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ABSTRACT
Childhood leukemia is a common paediatric cancer in the developed world and the 
biologically diverse subtypes of this disease are characterised by specific chromosomal 
translocations that alter the normal proliferative and survival signals of haematopoietic cells. 
Despite of greatly improved cure rate of childhood leukaemias over the past years, younger 
patients with acute leukaemias involving E2A-HLF and MLL-ENL translocations still confer a 
poor prognosis that is associated with a very unfavourable outcome. The incidence of relapse 
after complete remission seems to crucially depend on a small population of leukaemic stem 
cells that survive from the initial therapy and sustain the disease.
So far it has been unsuccessful to induce long-term gene silencing using siRNA technology 
in the primary haematopoietic cell lines and leukaemic stem cells. Thus, this project aimed to 
optimise the current 2nd generation of miR30-based shRNA lentiviral vector to achieve this. 
The silencing cassettes were delivered to the cells of interest by lentivirus and long-term 
expression was seen. The result revealed that effective E2A-HLF and MLL-ENL gene silencing 
was achieved while LM 02 gene expression was not significantly knocked down by the predicted 
LM02 shRNA constructs. The most efficient lentiviral vectors against specific genes will then 
be used to infect leukaemic cells to test the effect on aspects of the leukaemic phenotype.
Understanding of these fusion genes and identification of their downstream target genes in 
initiating and maintaining transformation events in the leukaemic stem cells may aid the 
development of revolutionary therapeutics that specifically target leukaemic stem cells. In 
conjunction with standard therapies, this approach could be more effective in treating MLL-ENL 
and E2A-HLF patients who tend to have an extremely unfavourable prognosis.
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A b b r e v ia t io n s
ALL acute lymphoblastic leukaemia
AML acute myeloid leukaemia
bHLH basic helix-loop-helix
bp base pairs
bZIP basic leucine zipper
cDNA complementary DNA
CMP common myeloid progenitor
CMV cytomegalovirus
CLP common lymphoid progenitor
CMP common myeloid progenitor
dd H2O double distilled water
DEPC diethyl pyrocarbonate
DNA deoxyribonucleic acid
dNTP dioxynucleotide triphosphate
dsRNA double-stranded RNA
DTT dithiothreitol
EDTA ethylamine diamine tetra acetic acid
EGFP enhanced green fluorescent protein
FACS fluorescence activated cell sorting
FCS foetal calf serum
Flt-3L fm s-like tyrosine kinase-3 ligand
GAPDH glyceraldehyde-3 -phosphate dehydrogenase
GMP granulocyte-macrophage progenitor
h hour(s)
HLF hepatic leukaemia factor
HOX homeobox
HPC haematopoietic progenitor cell
HSPC haematopoietic/stem progenitor cell
HSC haematopoietic stem cell
Ig Immunoglobulin
IL interleukin
kb kilobases
kDa kilo Daltons
LTR long terminal repeat
MEP megakaryocyte-erythroid progenitor
MFI mean fluorescence intensity
Min minute(s)
miRNA microRNA
MLL mixed lineage leukaemia
MOI multiplicity of infection
MPP multipotent progenitor
mRNA messenger RNA
NK natural killer
PAR proline and acidic amino acid rich
PCR polymerase chain reaction
PKR protein kinase RNA-activated
Pol II polymerase II
Pol III polymerase III
PPT polypurine tracts
PRIME potent RNAi using iR expression
PVDF polyvinylidene fluoride
RT-qPCR reverse transcriptase-quantitative PCR
RCL replication-competent lentivirus
RRE rev-responsive element
RISC RNA induced silencing complex
RNA ribonucleic acid
RNAi RNA interference
SAP shrimp alkaline phosphatase
rpm revolutions per minute
SCF stem cell factor
SDS sodium dodecyl sulphate
SDS-PAGE SDS-polyacrylamide gel electrophoresis
sec second(s)
SIN self inactivating vectors
shRNA short hairpin RNA
siRNA short interfering RNA
SFFV spleen focus forming virus
TAE Tris-acetate EDTA
TBS Tris-buffered saline
TBS-T Tris-buffered saline-Tween
TCR T-cell receptor
TEMED N,N,N',N'-Tetramethylethylenediamine
TF transcription factors
U unit(s)
UV ultraviolet
VSV-G vesicular stomatitis virus glycoprotein
WPRE woodchuck hepatitis virus posttranscriptional regulatory element
CHAPTER 1 
INTRODUCTION
1.1. HAEMA TOPOIESIS
Blood cell formation, termed haematopoiesis, is a exquisitely orchestrated and complicated 
process in which the generation of mature blood cells occurs from the differentiation and 
proliferation of a rare pluripotent haematopoietic stem cell (HSC) that resides in the bone 
marrow (Smith 2003). This allows the continuous replacement of the mature blood cells that 
have a short life span, sustaining the blood cell production. Haematopoiesis was found to occur 
in two waves at different organs. Primitive haematopoiesis occurs in the extraembryonic yolk sac 
followed by definitive haematopoiesis in the fetal liver region (Smith 2003). Primitive 
haematopoiesis is a transient phase of blood cell development that predominantly generates 
nucleated erythroid cells while definitive haematopoiesis is characterised by the production of 
cells of the myeloid and lymphoid lineages (Smith 2003). However, recent studies of yolk sac 
haematopoiesis have debated over several aspects of this paradigm (Smith 2003).
After birth, the bone marrow replaces the fetal liver as the dominant site of haematopoiesis 
and the number of HSCs is maintained in steady-state by continuous low-level turnover 
throughout adult life (Cheshier et al. l999;Kondo et al. 2003). It is popularly viewed that during 
haematopoiesis, commitment to either the lymphoid or the myeloid lineage is the first step of 
lineage restriction from primitive HSCs. As illustrated in the Figure 1.1, the common myeloid 
progenitor (CMP) are the clonogenic precursors of the granulocyte-monocyte restricted 
progenitors (GMPs) and the megakaryocyte-erythrocyte restricted progenitors (MEPs) that give 
rise to granulocytes and monocytes or platelets and erythrocytes whereas common lymphoid 
progenitor (CLP) develops into T cells, B cells, and natural killer (NK) cells. However, 
bipotential progenitors have been identified in both murine foetal liver and murine bone marrow 
which generated B cells and macrophages (Cumano et al. 1992;Montecino-Rodriguez, Leathers, 
& Dorshkind 2001). More recently, characterisation of multipotent progenitor (MPP) subsets 
challenges the widely-known model of haematopoiesis and suggests that the divergence of the
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lymphoid and myeloid lineages during early hematopoiesis occurs asymmetrically at distinct 
progenitor stages (Lai & Kondo 2006). Disturbances in normal haematopoiesis have been 
known to lead to blood disorders including leukaemia, characterised by the clonal proliferation 
of immature haematopoietic blood cells.
Haematopoietic stem cell
Common myeloid progenitor Common lymphoid progenitor
O
Megakaryocytic/erythroid
progenitor
Myelomonocytic
progenitor
 I___
Pro-B Pro-T Pro-NK
o o •
Erythrocytes Megakaryocytes Granulocytes Monocytes B cells T cells NK cells 
Figure 1.1 All the cells of the haematopoietic system originate from HSCs. HSCs 
differentiate into committed multipotent progenitors, CMPs and CLPs. CMPs give rise to 
erythrocytes, megaryocytes, monocytes and granulocytes whereas CLPs develop into B and T 
cells, also NK cells. Cells mature from the CMP through two intermediates, the MEP and the 
GMP (Janeway & Travers 1997).
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1.2. C h r o m o s o m e  t r a n s l o c a t io n s  in  c h il d h o o d  A c u t e  L e u k a e m ia s
Leukaemia is the most common paediatric cancer and the major morphological subtypes of 
leukemia, acute lymphoblastic leukaemia (ALL) and acute myeloblastic leukaemia (AML), are 
characterised by chromosomal translocations involving over 200 genes. Human acute 
leukaemias arise from blood cell progenitors that are developing in the lymphoid or myeloid 
pathway or from primitive stem cells with multilineage potential. The biological heterogeneity of 
childhood leukaemia is well documented (Biondi et al. 2000;Kersey 1997), with the most 
prevalent type being ALL which accounts for over 80% of all childhood cases in the population 
(Parkin et al. 1988). ALL is a stem cell disorder, characterised by the clonal proliferation and 
accumulation of lymphoblasts in the bone marrow that eventually spill into circulation, 
producing lymphocytosis (Randolph 2004). The precise pathogenetic events leading to the 
development of ALL are still unknown, but they are likely to affect genes that control lymphoid 
cell homoeostasis, resulting in dysregulated clonal expansion of immature progenitor cells. It is 
postulated that in most cases, childhood leukaemias may initially occur at prenatal stage (Bonnet 
& Dick 1997;Greaves & Wiemels 2003).
Chromosome translocations or other genetic aberrations in the stem cells have been 
proposed to be responsible for early or initiating transforming events in leukaemogenesis 
(Bonnet & Dick 1997;Greaves & Wiemels 2003). The process of chromosomal translocation 
involves the detachment and reattachment of a piece of one chromosome to another chromosome, 
bring two unrelated genes together. The result, referred to as gene fusion, can wreak havoc on 
the cell: they can turn off genes that normally direct haematopoietic differentiation, or/and, 
activate genes that help cell proliferation, leading to uncontrolled growth of immature cells. In 
childhood acute leukaemias, a large number of genetic alterations have been identified, these 
provide important diagnostic as well as prognostic implications that can guide the selection of 
therapy (Greaves & Wiemels 2003). Chromosomal abnormalities are the microscopically
12
visible indicators of genetic changes, and up to 80% of children with ALL have abnormal 
karyotypes (Harrison 2000).
The most frequent targets of chromosomal translocations in the acute leukaemias are genes 
that encode regulatory transcription factors, playing critical role in the control of blood cell 
development (Shivdasani & Orkin 1996). Two distinct mechanisms by which chromosomal 
translocations aberrantly activate genes encoding transcription factors (TF) have been elucidated 
(Figure 1.2) (Look 1997). TF proto-oncogenes are activated by the juxtaposition of a cellular 
oncogene (e.g. c-myc or BCL-2) with the promoter of a lineage-specific gene such as an 
immunoglobulin (Ig) gene (in B-cell malignancies) or a T-cell receptor (TCR) gene (in T-cell 
malignancies) (Rabbitts 1994). More commonly, the modular structure of transcription 
factors—including discrete DNA-binding, dimerisation, and trans-effector domains—allows 
normally unrelated sequences from different chromosomes to be recombined into hybrid genes 
that encode fusion products with unique properties including constitutive kinase activation (e.g. 
BCR-ABL and TEL-JAK2), but frequently, alters transcriptional regulation (Look 1997). The
chimeric transcription factors (e.g. E2A-HLF, PML-Rara and TEL-AML1, MLL-ENL)
resulting in the altered transcriptional regulation can lead to leukaemic transformation by 
disturbing stem cell development or lineage specification in haematopoiesis (Rabbitts 1994).
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A  R Coding [ R j  .Coding
Ig or TCR gene   TF proto-oncogene
O ®
TF oncogene
B  R Coding ®  C oding |
T^ ene ' TF gene
Chimeric 
c o d ii
Chimeric TF oncogene  
Figure 1.2. Two distinct mechanisms by which chromosomal translocations aberrantly 
activate genes encoding TF. (A) TF proto-oncogenes that are silent or expressed at low levels in 
the progenitor cells of a particular lineage may be activated when placed under the control of 
potent enhancer elements within the regulatory region (R) of a gene that is normally highly 
expressed. (B) More commonly, chromosomal breakpoints occur within introns, between the 
coding sequences of each of two transcription factor genes on different chromosomes, producing 
a fusion gene that encodes a chimeric transcription factor with altered function (Look 1997).
1.2.1. E2A-HLF fusion protein
The E2A-gene-encoded transcription factors, E l2, E47 and E2-5 resulting from alternative 
splicing of exons, have been found to contain the basic helix-loop-helix (HLH) domain, which 
mediates binding to specific E-box elements, and is relevant in immunoglobulin and T-cell
14
receptor gene rearrangements during development (Murre et al. 1989). Homodimers of E2A 
proteins (Class I HLH proteins) are required for the proper E2A function in B cells, whereas 
tissue-specific Class II HLH proteins, such as MyoD (muscle), Tall and Lyll (T cells), and 
NeuroD (neurons) heterodimerise with E2A to cooperatively mediate basic HLH functions 
(Seidel & Look 2001). Furthermore, activity of Class I HLH proteins is antagonised by 
heterodimersation with Class V HLH proteins (Id proteins) as they lack a functional basic DNA 
binding region. E2A serves as a tumor suppressor par excellence, mediating essential functions 
in the regulation of differentiation, maturation, cell fate, and the cell cycle, so that modifications 
of its expression level tends to contribute in important ways to leukaemogenesis (Seidel & Look
2001). Moreover, several studies have indicated that E2A component appears to be sufficient to 
trigger oncogenic transformation if mis-expressed and dimerised due to its fusion partner (Bayly 
& LeBrun 2000;Inukai et al. 1998;Kamps, Wright, & Lu 1996;Monica et al. 1994). E2A gene 
has been reported to involve in transcriptional regulation of cysteine rich LIM-domain-only 
genes LM 02 , encodes a nuclear protein that is necessary for embryonic erythropoiesis and for 
adult haematopoiesis (Grutz et al. 1998). These functions seem to be mediated through 
participation of LM 02 protein in the transcription factor complex which includes E2A, TALI, 
GATA1 and LDB1 in erythroid cells (Osada et al. 1995;Wadman et al. 1997). Within this 
transcription complex, LM02 mediates the protein-protein interactions by recruiting LDB1, 
whereas TALI, GATA1, and E2A regulate the binding to specific DNA target sites (Grutz et al. 
1998). Aberrant expression of LM02 protein can block early stages of T cell differentiation, 
which in turn, contributes to the formation of the T cell lymphatic leukaemia. Of note, 
constitutive expression of LM02 by itself is not enough for oncogenic transformation, and 
additional mutation, are required to induce malignant T-ALL clone (Rabbitts 1998).
Hepatic leukaemia factor (HLF) belongs to the PAR (proline and acidic amino acid-rich) 
subfamily of basic leucine zipper (bZIP) transcription factors which was first identified due to
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nature of its fusion to E2A in ALL (Hunger et al. 1992;Inaba et al. 1992). HLF is normally 
expressed in human brain, lung, liver and kidney and was found to be closely related to the genes 
that regulate developmental stage-specific gene expression (Hunger, Ohyashiki, Toyama, & 
Cleary 1992;Inaba et al 1992). HLF is not initially believed to be expressed in haematopoietic 
and lymphoid cells, however a recent report showed that HLF was expressed in erythroid cells 
(Crable & Anderson 2003;Hunger et al. 1992;Inaba et al. 1992). Analysis of rat HLF 
expression revealed that the rat HLF gene encoded two major transcriptional activators HLF43 
and HLF36, detected in the liver which had distinct tissue distribution and were expressed in 
different circadian fashion (Falvey, Fleury-Olela, & Schibler 1995). Furthermore, compelling 
evidence suggested that HLF regulates normal expression of liver-specific genes in the liver as 
HLF have different activation potentials for the promoters of the cholesterol 7a hydroxylase 
promoter, albumin promoter, Factor VIII and Factor IX promoters (Begbie et al. 1999;Falvey et 
al. 1995;Newcombe et al. 1998). HLF has also been shown to transactivate the LM02 promoter 
in reporter assays in an erythroid cell line (Crable and Anderson, 2003).
E2A-HLF, the chimeric fusion protein resulting from the leukaemogenic translocation 
t(l 7; 19)(q22;pl 3) gives rise to a distinct but fortunately rare form of high risk pro-B-cell ALL in 
adolescents, by acting as a anti-apoptotic factor, interfering with an early step in apoptotic 
signaling (Seidel & Look 2001;Yeung et al. 2006). The oncogenic ability of E2A-HLF has been 
observed in mice model which has been shown to require at least one of the two trans-activation 
domains of E2A, as well as the leucine zipper dimerisation domain of HLF (Yoshihara et al. 
1995). The E2A-HLF fusion protein contains the N-terminal transactivation domains of E2A 
joined to the basic region and leucine zipper domain of HLF (Hunger et al 1992;Inaba et al. 
1992). E2A-HLF fusion, via chromosomal translocation, might actively employ a survival 
signaling pathway to perform its oncogenic functions which could be the major leukaemic event 
in addition to the perturbation of normal E2A function (Seidel & Look 2001).
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1.2.2. MLL-ENL fusion protein
The MLL (Mixed Lineage Leukaemia or Myeloid/Lymphoid Leukaemia) gene on 
chromosome 1 lq23 is frequently involved in chromosomal translocations associated with human 
acute leukaemias (Ziemin-van der et al. 1991). These translocations lead to fusion genes 
generally resulting in novel chimeric proteins containing the amino terminus of MLL fused 
in-frame to one of about 40 distinct partner proteins, including AF6, AF9, AF10 and ENL 
(Mitterbauer-Hohendanner & Mannhalter 2004). Abnormalities involving the MLL gene are 
observed in infant leukaemias of myeloid and lymphoid lineage and in treatment-induced 
secondary leukaemias. In the majority of cases, chromosomal abnormalities involving the MLL 
gene are indicators of very poor prognosis, especially the ones associated with pro-B ALL found 
in infants (< 1 year). This gene has been shown to code for an unusually large protein (431 
kDa), that is a homologue of Drosophila trithorax and is involved in homeotic gene regulation 
(Tkachuk, Kohler, & Cleary 1992). Studies in mice have revealed that disruption of the MLL 
gene abolished homeodomain (HOX) gene expression (Mitterbauer-Hohendanner & Mannhalter 
2004). HOX TF genes are highly conserved in mammals, which are important for embryonic 
development as well as for the regulation of haematopoietic differentiation (Lawrence et al. 
1996;Look 1997). A sizable amount of data suggested that MLL is not necessary for the initial 
regulation of HOX gene expression, but is required for the maintenance of gene expression 
necessary for embryonic development haematopoiesis (Hanson et al. 1999;Hess et al. 1997;Yagi 
et al. 1998;Yu et al. 1995;Yuetal. 1998).
In studies of a chimeric protein involving t( 11; 19) translocation, fusion of the 
amino-terminal AT-hook motifs of the MLL gene on chromosome 11 to a previously undescribed 
protein (62 kDa) chromosome 19 was identified, named ENL (Tkachuk et al. 1992). AT hooks 
was discovered to mediate specific binding to the minor groove of AT-rich DNA (Tkachuk et al. 
1992). Through them, MLL might stabilise protein-DNA interactions by inducing conformational
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changes, which then facilitate the binding of specific factors that regulate target gene 
transcription (Mitterbauer-Hohendanner & Mannhalter 2004). ENL was shown to function, in 
both myeloid and lymphoid cells, as a nuclear protein in which the minimal portion of ENL 
required for the activation of transcription was localised to the C-terminal 90 amino acids 
(Rubnitz et al. 1994).
A number of studies have demonstrated the potential transforming effects of MLL-ENL by 
different experimental models. Laveau et al. demonstrated a direct role for MLL-ENL, by 
retroviral transduction, in the immortalisation and leukaemic transformation of a myeloid 
progenitor and support a gain-of-function mechanism for MLL-ENL-mediated leukaemogenesis 
(Lavau et al. 1997). Cells transduced with MLL-ENL induced myeloid leukaemias in syngeneic 
and SCID mice. Moreover, wildtype ENL or a deletion mutant of MLL-ENL lacking the ENL 
component did not possess in vitro transforming capabilities. AT hook motifs and 
methyltransferase homology domain of MLL as well as the carboxyterminal 84 amino acids of 
ENL, which encode two predicted helical structures, are essential for the full transforming 
activity of MLL-ENL (Slany, Lavau, & Cleary 1998). It correlates the biological function of an 
MLL fusion partner with the transforming activity of the chimeric protein.
1.3  F a il u r e  o f  C u r r e n t  Tr e a t m e n t
Combination chemotherapy, involving vincristine, dexamethasone, asparaginase, 
daunoyubicvin, doxorubicin, methotrexate etc, is the most common regimen in treating the 
childhood leukaemias. Although optimisation of existing treatment modalities result in 
long-term survival in approximately 80% of the cases (Pui, Relling, & Downing 2004), the 
prognosis still remains poor in some subgroups (e.g. involving MLL-ENL and E2A-HLF 
chromosomal translocations) of patients, owing to the clinical problems like considerable toxicity, 
morbidity, emergence of secondary complications etc. Clearly, there is a need to identify novel
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drug targets whose expression is dysregulated by these translocations, in hope to bring 
significant improvement in treatment options.
The treatment outcome is age-dependent and infants with ALL have not benefited from the 
greatly improved treatment regimens that have developed over recent decade. Although 
morphological complete remission is achieved in the vast majority (c. 95%) of these very young 
children (Frankel et al. 1997;Reaman et al. 1999), a favourable outcome usually is hampered by 
an exceedingly high relapse rate. Numerous data suggested that cellular drug resistance seems to 
significantly contribute to the dismal prognosis of childhood acute leukaemias involving 
E2A-HLF and MLL-ENL translocations (Dordelmann etal, 1999; Riehm et al, 1987). 
Although current anticancer therapies have produced dramatic response at the early stage of the 
treatment by directly against and reducing the bulk of the tumour mass (i.e. the fast dividing 
cells), a small numbers of slow-/non-dividing cells (known as leukaemia stem cells, LSCs) that are 
presumably even more resistant than the bulk of the leukaemic cell, as a result of selection, may 
contribute to the re-emerging leukaemia.
1.4 L e u k a e m ic  S t e m  C e l l s
LSCs seem to be surprisingly different from the normal blast and are presumed to arise 
from mutations in normal haematopoietic stem cells or progenitor cells. They are difficult to be 
eradicated as their quiescent property renders them remain unresponsive to the cell cycle- 
specific cytotoxic agents commonly used to treat leukemia and survive from the initial therapy, 
thus contributes to failure of the treatment. LSCs may undergo mutations and epigenetic changes, 
further leading to drug resistance and relapse. Reflecting this point, most patients who experience 
a relapse do not survive their disease (e.g. Reaman et al, 1999). Recent data suggest that mature 
leukemia cells may acquire LSC characteristics, thereby evading chemotherapeutic treatment and 
sustaining the disease. Thus, therapy directed at stem cell-specific targets, rather than
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cancer-specific targets, may offer the best chance of eliminating the LSCs as a new goal of 
therapy in leukemia.
It is generally accepted that self-renewal is the hallmark property of stem cells in both 
normal and neoplastic tissues, thus recent research has been in attempt to identify the genes, 
transcription factors, and cell cycle regulators that modulate the self renewal and differentiation 
of HSCs by over-expression and knockout experiments. Genes (such as SCL, GATA-2, LMO-2, 
and AML-1) deregulated in leukaemia are those govern the transcriptional regulation of early 
hematopoiesis(Ravandi & Estrov 2006). For example, SCL is normally expressed in HSCs and 
immature progenitors and is down-regulated as differentiation proceeds(Ravandi & Estrov 2006). 
Aberrant expression of SCL, seen in children T-cell ALL, results from collaboration with other 
oncoproteins through chromosomal aberrations and initiates malignant transformation(Ravandi 
& Estrov 2006). Deregulated expression of Hox family members such as HoxA9 is commonly 
observed in AML(Huntly & Gilliland 2005). The importance of Wnt signaling pathway has been 
recently determined in the regulation of haematopoietic stem and progenitor cell (HSPCs) 
functions (Huntly & Gilliland 2005). Activation of Wnt signaling has been shown to expand the 
transplantable HSC pool in long-term cultures, also, to increases the expression HoxB4 and 
Notch-1 that are important in HSC self-renewal(Huntly & Gilliland 2005). The Notch/Jagged 
pathway is important in regulating the integration of extracellular regulatory signals controlling 
HSC fates(Huntly & Gilliland 2005). Of interest, the gene encoding the Notch receptor was 
originally identified as the gene rearranged by recurrent chromosomal translocations in some 
patients with T-cell ALL (Ravandi & Estrov 2006). Other transcription factors and cell cycle 
regulators associated with oncogenesis, such as Bmi-1 and Sonic hedgehog, may play roles in the 
regulation of proliferation of both HSCs and LSCs (Huntly & Gilliland 2005). Further studies 
of these transcription factors in HSCs and the mechanisms causing their deregulation are likely to 
provide us with better targets for development of disease-specific therapies.
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1.5. P r e v io u s l y  id e n t if ie d  t a r g e t s  ofE2A-HLF
The changes in the global expression of genes resulted from chromosomal aberrations and other 
genetic lesions have been determined by the use of microarray technology. Microarray 
technology, evolved from southern blotting, enables tens of thousands of genes to be analysed 
simultaneously in a single experiment to delineate differential expression of genes in the cells 
that have been subjected to a particular treatment or express a specific protein. The 
characteristic gene expression profiles for the different chromosomal abnormalities can provide 
information regarding the underlying biology of the leukaemia and identification of molecular 
targets for therapeutic intervention. Expression of E2A-HLF has been proposed to alter the 
transcriptional profile of pro-B cells that carry the t(17;19) translocation. To elucidate the role of 
E2A-HLF in leukaemic phenotype of ALLs, studies have been previously carried out by Jenny 
Yeung in Brady’s lab (J. Yeung PhD thesis, UCL 2005 and Yeung et al. manuscript in 
preparation) to identify its downstream targets which may play a vital role in inhibiting apoptosis 
or other leukaemogenic processes by microarrays.
The chimaeric nature of the E2A-HLF transcription factor suggested that the genes that it 
regulates are likely to be different to those normally regulated by either E2A or HLF. 
Microarray studies showed significant changes (> 1.3-fold) of 46 genes in pro-B cells expressing 
E2A-HLF. Of 46 genes, 26 genes were up-regulated by the expression of E2A-HLF, including 
BCL2 antiapoptotic protein and LM02 transcriptional factor. The co-expression of both genes 
have been found to immortalise haematopoietic progenitor cells while either LM 02 or BCL2 
expression alone did not confer cell survival.
1.6 L e n t iv ir a l -b a s e d  RNA In t e r f e r e n c e  (RNAi) Te c h n o l o g y
While conventional methods (such as generation of knockout and transgenic animals) to 
decode the function of novel genes still remain laborious, time-consuming, and expensive, RNAi
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is rapidly becoming the preferred system for targeted genetic manipulation by inducing 
posttranscriptional gene silencing in which gene function can be approached on a single-gene or 
genome-wide level (Hannon 2002;Silva et al. 2005). The RNAi in combined with the lentiviral 
vector-mediated gene delivery to a wide range of cell types offers great possibility of long-term 
down-regulation of specific target genes that are abnormally up-regulated in the diseased cells 
both in vitro and in vivo. Thus, the use of silencing lentivectors allows for a rapid and convenient 
way of assessing how the potential candidate genes contribute to the development of leukaemia 
in eukaryotic cells and to further determine if the genes are potential drug target candidates.
RNAi is an evolutionary conserved mechanism that has been exploited in organisms 
ranging from plants to fungi to animals, mediates resistance to both endogenous parasitic and 
exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes 
(Hannon 2002). The RNAi machinery can be programmed by exogenous or endogenous 
sources of double-stranded RNA (dsRNA). RNAi with long dsRNA (500 bp or more) works 
well for Caenorhabditis elegans and Drosophila melanogaster, in most mammalian cells, 
however, this provokes a strong cytotoxic response, presumably because of the activation of 
antiviral responses, which results in the general inhibition of protein synthesis (Hunter et al. 
1975). This aspecific interferon response was circumvented when it was discovered that short 
(<30 bp) synthetic dsRNAs, namely short interfering RNA (siRNA), can trigger silencing of 
gene expression with exquisite specificity, but small enough to evade significant detection by the 
interferon responses (Elbashir et al. 2001). Briefly, endogenous RNAi pathway is harnessed by 
introduction of synthetic dsRNA into the mammalian cell, which is then processed into siRNA 
with specific structure (short duplexes of about 19-21 nt in length, bearing 2 nucleotide (nt) 3’ 
overhangs) by cytoplasmic RNase III enzyme Dicer (Fire et al. 1998;Tomari & Zamore 2005). 
siRNA is subsequently taken up by RNA induced silencing complex (RISC). The antisense 
strand (complementary to the target gene) of siRNA then associates with the mRNA target for
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destruction by Ago 2 nuclease, while the “sense” strand (the strand that has exactly the same 
sequence as a target gene) is released and degraded (Elbashir et al. 2001;Hamilton et al. 
2002;Martinez et al. 2002).
An important development in RNAi technology was the finding that siRNAs could be 
genetically encoded in an organism by expressing a short hairpin RNA (shRNA), consisting of a 
sequence of 21-29 nt, a short loop region, and the reverse complement of the 21- to 29-nt region 
driven by a polymerase III (pol III) such as those that drive expression of the endogenous U6 
small nuclear RNA or the HI RNA (Brummelkamp et al. 2002;Lin et al. 2004;Paddison et al.
2002). When transcribed in vivo, this short transcript folds back on itself to form a hairpin 
structure, which is converted by endogenous nuclease into short RNAs that are recognised by the 
RISC and used to target mRNA for destruction. This breakthrough discovery provided the base 
for the design of l st-geneartion shRNA plasmids for long-lasting gene silencing in the 
mammalian cells (Figure 1.3). *
More recently, l st-generation shRNA design has been optimised to achieve highly efficient 
target gene knockdown by creating an expression cassette that embeds the sequence of shRNA 
into the larger fold of a ubiquitous microRNA (miRNA), thus shRNA is processed by the 
endogenous-like miRNA to perform gene silencing (Figure 1.3). During the process, miRNAs 
are initially transcribed by polymerase II (pol II) as long pre-miRNA and then processed by the 
nuclear RNase III enzyme Drosha to give the -60 nt pre-miRNA hairpin intermediate, which are 
exported to the cytoplasm (Cullen 2006). The subsequent processing steps of pre-miRNAs 
involving Dicer cleavage and RISC-mediated mRNA degradation are indistinguishable to that of 
shRNAs in human cells. Since the design of miRNA-based shRNA mimics endogenous trigger 
of RNAi pathway , 2nd generation siRNA vector containing pol II promoters for expression of 
shRNAs in the context of miRNA precursors can result in the production of a mature siRNA 
with continuous expression and subsequent degradation of the target mRNA, thus stable gene
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knockdown can be established (Grishok et al. 2001;Hutvagner et al. 2001). 2nd generation siRNA 
design has been experimentally proven to outperform the 1st generation (Stegmeier et al. 2005).
1st G enera tion
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S V hCD2
hCD2“
shRNA
2nd G enera tion
Pol II
miRNA-based shRNA 
*
eG FP
—  GFI miRNA
ShRNA
Figure 1.3. Design of 1st and 2nd generation of lentiviral-based siRNA vectors. In the 1st
generation, the expression cassettes have 19-29 nt stem loop shRNA within minimal flanking 
RNA sequence and are traditionally expressed from pol III promoters, such as U6 whereas hCD2 
surface marker is expressed from another promoter. In contrast, 2nd generation design contains 
the maturally occurring primary miRNA presursors fold extensively beyond the core stem-loop 
shRNA structure, which is co-expressed with eGFP under the control of the high-copy Pol II 
promoter. Unlike 1st generation, promoter in 2nd generation can be changed with alternative 
promoter.
Over the past decade, considerable progress has been accomplished in the design of gene 
delivery vehicles based on HIV-1, the best characterised of the lentiviruses. The HIV-1 
genome contains 9 open reading frames encoding at least 15 distinct proteins involved in the 
infectious cycle, including structural and regulatory proteins. In addition, there are a number of 
czs-acting elements required at various stages of the viral life cycle. These include the long
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terminal repeats (LTRs), the TAT activation region (TAR), splice donor and acceptor sites, 
packaging and dimerisation signal (^), Rev-responsive element (RRE) and the central and 
terminal polypurine tracts (PPT) (Salmon & Trono 2002). Lentiviral vectors derived from 
HIV-1 offer several advantages over other vectors, including stable integration into the host-cell 
genome, effective infection of a wide variety of dividing and nondividing cells, resulting in 
sustained expression of the transgene (Kafri et al. 1997;Miyoshi et al. 1997;Miyoshi et al. 
1999;Naldini et al. 1996;Uchida et al. 1998). Thus, lentiviral-based RNAi experiment is 
becoming a useful to effectively transduce quiescent cells and induce long-term gene silencing 
(Figure 1.4).
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Figure 1.4. Lentiviral infection and expression in the mammalian RNAi experiment. The
HIV-1 like virus enters the cell cytoplasm by a process in which the viral envelope merges, via 
recognition of receptors/co-receptors displayed on the host cell surface, with a host cell
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membrane while viral RNA are released into the cells and imported into the nucleus 
compartment where the viral RNA are converted to viral DNA by HIV enzyme reverse 
transcriptase. Viral transfer vector used to generate the HIV-1 like virus has been 
self-inactivated, thus, they are replication-defective. Upon stable integration of viral DNA into 
host cell genome, two modes of RNAi action i.e. siRNA and miRNA can occur, depend on 
whether 1st generation or 2nd generation shRNA vectors, respectively, is used. With 1st generation, 
shRNA duplex derived from the host genome is exported, by Exportin5, to the cytoplasm where 
the loop is cut by Dicer (blue). Duplex siRNAs are unwound by an ATP-dependent helicase 
(orange) and one strand (red) is incorporated into a large multiprotein nuclease complex, RISC, 
while the other strand (black) is removed. Incorporation of small RNA activates RISC (green). 
Guided by the antisense strand of siRNA, the Ago2 endonuclease (pink) in the activated RISC 
recognises and cleaves the corresponding mRNA (brown), with a resultant decrease in the 
steady-state levels of mRNA. With 2nd generation vector, the individual miRNA-containing 
hairpin precursor (pre-miRNA) is excised from the primary miRNA by Drosha in the nucleus 
that is then exported to the cytoplasm. The subsequent pathway of miRNA action mode (2nd 
generation vector) in the cytoplasm is indistinguishable to that of siRNA (1st generation vector).
1 .7  O v e r v ie w  O f  P r o j e c t
Altered gene expression resulted from chimeric fusion proteins, such as E2A-HLF and 
MLL-ENL, is associated with the subtypes of childhood acute leukaemias. Despite of the 
overall cure rate has significantly increased to nearly 80%, the subtypes of childhood acute 
leukaemias characterised by E2A-HLF and MLL-ENL translocations are still of poor prognosis. 
Thus much effort has gone towards identifying the novel drug candidate targets that either 
exhibit unwanted or inadequate activity in the diseased tissues, to improve the current treatment 
options. Brady, H.J.M. and his colleagues have previously identified, by Affimetrix experiment, a 
number of candidate target genes whose expression is up-regulated by certain translocations,
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including LM 02  and BCL2 by E2A-HLF in pro-B cells. They also compared the effectiveness of 
the 1st and 2nd generation of lentiviral vectors (Figure 1.3) in establishing a knock down 
phenotype. In first generation vector, shRNA expression driven by pol III (U6) promoter is 
located upstream of the hCD2 surface marker that is expressed from a separate promoter, SV40. 
On the other hand, shRNA and expression marker, eGFP (enhanced green fluorescent protein) 
are transcribed from the same promoter, CMV (human cytomegalovirus immediate-early). In 
contrast to 1st generation vector, 2nd generation vector is a miRNA-based shRNA vector in which 
shRNA is embedded in a miRNA fold like endogenous miRNA-30, more efficient knockdown 
was observed. An added bonus of the 2nd generation vector is the ease of cloning that allows 
quick insertion of any shRNA into the miRNA fold, together with a promoter of choice (i.e. pol 
II CMV promoter can be changed with other promoters). They discovered that both 1st and 2nd 
generation vectors could not achieve long-term expression in primary haematopoietic cells, thus 
it was a must to change the promoter for more effective knockdown. Since pol III promoter in 
the 1st generation vector can not be changed, 2nd generation vector was preferred for the RNAi 
experiment in the primary haematopoietic cells.
The aim of this project was to establish long-term gene silencing in HSCs and primary 
haematopoietic cells with the use of re-engineered 2nd generation of lentiviral vector as well as to 
establish knock down efficiency in the primary immortalised haematopoietic cell lines. The 
strategy involved replacing the CMV with a more effective promoter and then cloned the 
miR30-based shRNAs that specifically target LM 02 , HLF, MLL and ENL genes into the vector. 
Not all rationally designed shRNAs will knock down gene expression at the same level, and 
therefore, the knockdown efficiency of the shRNA vectors generated were evaluated and 
established by western blot and RT-qPCR to detect the expression levels of exogenous protein 
and mRNA, respectively.
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CHAPTER 2  
MATERIALS AND METHODS
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Chemicals were purchased from VWR, Poole, Dorset, UK unless otherwise stated. 
All tissue culture reagents were from Invitrogen, Paisley, UK unless otherwise stated. 
Enzymes were purchased from Promega, Madison, Wisconsin, USA. 
Oligonucleotides were purchased from Sigma Genosys, Haverhill, UK.
All recombinant cytokines were purchased from Peprotech EC, London, UK.
2.1. BUFFERS AND SOLUTIONS 
Table 2.1. Buffers and solutions
Buffer or solution Final concentration of components
Luria-Bertani (LB)-agar LB broth medium plus 15 g/l agar.
LB broth 1.0% tryptone, 0.5% yeast extract, 1.0% NaCI (pH 7.0).
FACS buffer 0.1% BSA and 0.1% azide su spended  in PBS
RIPA lysis buffer 150 mM NaCI, 1 % Triton X-100, 0.5% sodium deoxycholate, 0.1% 
SDS, 50mM Tris-HCI (pH 8.0), 5mM EDTA. One Com plete Mini 
p ro tease inhibitor cocktail tablet (Roche, Lewes, UK) w as dissolved 
per 10 ml lysis buffer.
2x Sam ple Buffer 100 mM Tris-HCI (pH 6.8), 4% SDS, 0.2% bromophenol blue, 20% 
glycerol (Sigma). Dithiothreitol (DTT) w as added to protein sam ples 
to final concentration of 200 mM.
SDS-PAGE electrophoresis buffer 25 mM Tris-HCI (pH 7.5), 192 mM glycine, 0.1% SDS.
Protein transfer buffer 5 mM Tris-HCI (pH 8.3), 192 mM glycine, 20% methanol.
Tris-buffered saline (TBS) 
Tris-buffered saline -
20 mM Tris-HCI (pH 7.5), 150 mM NaCI.
Tween 20 (TBS-T) 20 mM Tris-HCI (pH 7.5), 150 mM NaCI, 0.1% Tween 20 (sigma)
TAE buffer 40 mM T ris-acetate and 1 mM EDTA at pH 8.3.
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2.2. C e l l  C u l t u r e
Cells were maintained at 37 °C with 5% CO2 in a humidified atmosphere. Viable-cell 
counts were performed and determined by trypan blue dye exclusion with a Hemacytometer. 
Complete medium was sterile filtered using 0.22 pm filter (Millipore, Watford, UK) and stored 
at 4°C until use.
2.2.1. 293 FT
293 FT cells, human embryonic kidney epithelial cells, are ecotropic lentivirus packaging 
cell line. They stably and constitutively express the SV40 large T antigen and were cultured in 
D-MEM, 10% foetal bovine serum (FBS), 0.1 mM MEM Non-Essential Amino Acids (NEAA), 
2 mM L-glutamine, 1% Pen-Strep (penicillin,streptomycin) and 0.5 mg/ml Geneticin. 
Additional 1 mM MEM Sodium Pyruvate was added for virus production.
2.2.2. Baf-3, 32D
Baf-3 cells (early precursors of B lymphocytes from murine bone marrow) and 32D cells 
(murine myeloid cell line) are dependent on the cytokine interleukin-3 (IL-3) for proliferation. 
The were grown at concentrations of lx l0 5 -  5x10s cells/ml and maintained in RPMI 1640 
containing 10% foetal calf serum (FCS) (Globepharm, Surrey, UK), 10 % murine IL-3 
supplement, 0.5 mg/ml geneticin, 1% Pen-Strep, and 2 mM L-glutamine.
2.2.3. C l l f SEMK2
32D-derived C ll cells (MLL-ENL) and human leukemia cell line SEMK2 (MLL-AF4) 
were cultured in RPMI 1640 medium containing 10% FCS, 1% Pen-Strep and 2 mM 
L-glutamine. Cultures were maintained by the addition of fresh medium or replacement of 
medium. To split confluent cells at regular time interval, cell density between 2 xlO5 and 1 x 
106/ml cells were used for seeding.
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2.2.4. E2A-HLF, LM02/BCL2 primary immortalised haematopoietic cells
They are lymphoid lineage cell lines, cultured in IMDM medium containing 10% FCS, 
2mM, L-glutamine, 100 U/ml penicillin 100 pg/ml streptomycin, 50 pM 2-ME withlOO ng/ml 
stem cell factor (SCF), 200 ng/ml IL-7 and 10 ng/ml fins-like tyrosine kinase-3 ligand (Flt-3-L). 
To subculture confluent cells at regular time interval (approximately 3 to 4 days), cell density 
between 1 xlO5 and 1 x 106/ml cells were seeded. Cells were cultured until confluent.
2.2.5. MLL-ENL primary immortalised haematopoietic cells
It is myeloid lineage cell line, cultured in IMDM medium containing 10% FCS, 2mM, 
L-glutamine, 100 U/ml penicillin 100 pg/ml streptomycin, 50 pM 2-ME withlOO ng/ml stem cell 
factor (SCF), 10 ng/ml IL-3 and 10 ng/ml IL-6. To subculture confluent cells at regular time 
interval (approximately 3 to 4 days), cell density between 1 xlO5 and 1 x 106/ml cells were 
seeded. Cells were cultured until confluent.
2.3. G e n e ra l m o le c u la r  b io lo g y  tech n iq u es
2.3.1 Restriction digests
1 or 5pg of plasmid DNA were digested in a total reaction volume of 20 pi, or 100 pi for 
diagnostic digests and opening a vector/excising an insert, respectively. IX restriction enzyme, 
10X restriction enzyme buffer (refer to Promega catalogue), and 10X BSA were added (if 
applicable) to the DNA. Sterile double distilled water (dd FLO) was added to make up the 
total volume. The digest was incubated at the appropriate temperature (refer to Promega 
catalogue) for 1 hour (h) diagnostic digest or at least 2 h in preparation for a ligation. The 
efficiency of the digest reaction was checked by loading a tenth of the reaction (or the whole 
diagnostic digest) onto an agarose gel for electrophoresis.
31
2.3.2 PCR-quick purification
PCR products and vector DNA were purified by QIAquick PCR Purification K it (Qiagen) 
and eluted in 30 pi dd H2O. Please refer to the manufacturer’s instructions for the detailed 
protocol.
2.3.3 Alkaline phosphatase treatment
2pl of shrimp alkaline phosphatase (SAP) was added to dephosphorylate the 5' 
phosphorylated ends of the purified vector DNA (30pl) after the reaction mixture had been 
heat-inactivated. After incubation at 37 °C for 2 h, the SAP was heat-inactivated for 40 
minutes (min) at 65 °C.
2.3.4 Gel preparation and running
Appropriate amount of agarose (Invitorgen) was heat-dissolved in 150mL IX TAE buffer 
(Table 2.1). Ethidium bromide (final concentration 0.5 ug/ml, Invitrogen) was added when the 
gel was hand-warm, then gel poured. Migration was performed under a voltage of -150V, 20 to 
30 min for diagnostic gels and 60 to 90V, 1 to 1.5 h for purification gels. Ready-to-use 1 kb Plus 
DNA ladder {Invitrogen) was added with 10X BlueJuic Gel Loading Buffer {Invitrogen) at a 
concentration of 2X for electrophoresis of DNA standards was loaded on agarose gels to 
determine the length of the DNA fragments.
2.3.5 UV exposure
To visualise the DNA bands, the gels were exposed to UV light and photographed.
2.3.6 Gel purification
DNA fragments for ligation were extracted from the gel using the QIAGEN MinElute Gel 
Extraction K it, eluting the DNA in 20pl of dd H2O. Please refer to the manufacturer’s
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instructions for the detailed protocol.
2.3.7 Generation of blunt ends by Large Klenow Fragment
4 pg of DNA (in a volume of 20 pi) was digested with an appropriate restriction enzyme 
that generated a 5’- overhang, and were then purified by QIAquick PCR Purification Kit. The 
optimal reaction conditions for filling 5’-protruding ends were: 50 mM Tris-HCI (pH7.2), 10 
mM MgS04, 0.1 mM DTT, 40 pM of each dNTP, 20 pg/ml acetylated BSA and 1 unit of 
Klenow Fragment per microgram of DNA. The reaction was incubated at room temperature for 
10 min, and stopped by heating for 75 °C for 10 min.
2.3.8 Ligation
The ligation reactions were set up with 1 OOng of dephosphorylated vector. Purified insert
was added according to the vector/insert molar ratios of 1:3 and a control reaction for SAP 
activity with a ratio of 1:0. Ligation reactions were set up with the vector DNA, insert DNA and 
2pl 10X ligation buffer, adjusted to 20 pi with dd H2O, 1 pi of T4 DNA ligase was added and 
left for 2-4 hours at the room temperature or at 16°C over night.
2.3.9 Transformation
2 pi of a ligation reaction was gently mixed with 50 pi competent E. coli (strain: DH5a, 
STBL3, Invitrogen) and incubated on ice for 5 to 30 min. Cells were heat shocked at 42 °C for 30 
seconds (sec). 250 pi room temperature SOC medium was added to the cells and incubated at 37 
°C for 1 to 2 h with vigorous shaking. 100 pi to 200 pi of bacterial culture was plated on to
LB-agar plates (Table 2.1) containing ampicillin (50 pg/ml) and incubated at 37°C overnight.
2.3.10 Small-scale plasmid preparation (Miniprep)
5 ml of LB broth (Table 2.1) containing ampicillin (50 pg/ml) was inoculated with a
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bacterial colony and cultured overnight at 37 °C with vigorous shaking. Plasmid DNA was 
extracted from 1.5 ml of bacterial culture using QIAprep Spin Miniprep kit {Qiagen, Crawley, 
UK) according to manufacturer’s instructions. DNA was eluted in 50 pi of sterile dd H20 and 
stored at -20 °C.
2.3.11 Large-scale plasmid preparation (Maxiprep)
3 ml of LB broth containing ampicillin (50 pg/ml) was inoculated with a bacterial colony or 
left-over culture from Miniprep and cultured for 6 h. 400 ml of LB broth containing ampicilin
was inoculated with 3 ml of the starter culture and cultured overnight at 37 °C with vigorous
shaking. Plasmid DNA was extracted from 2 ml of bacterial culture using a Plasm id Maxi kit 
(Qiagen) according to manufacturer’s instructions. DNA was eluted in 500 pi of dd H2O
2.3.12. Polymerase chain reaction (PCR)
PCR was used to incorporate XhoI/EcoRI flanking restriction sites to the hairpin oligo prior 
to cloning into appropriate vectors. PCR was carried out in a 50 pi reaction volume containing 
100 ng template oligo (Table 2.2, Sigma), 1 x thermoPol Buffer (NEB), 0.2 mM deoxynucleotide 
triphosphate (dNTP) mix {Promega), 2 mM MgS04, 0.5pM of pSMS2C forward and reverse 
primers (Table 2.3) and 1 U VENT polymerase {NEB). All components were added on ice. 
Cycling conditions were 94 °C for 5 min, 12 cycles of 94 °C for 30 sec, 54 °C for 30 sec and 75 
°C for 32 sec followed by final extension at 75°C for 2 min. Following PCR amplication, PCR 
products were purified with PCR purification columns {QIAquick PCR Purification Kit) and 
eluted with 50 pi elution buffer.
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Table 2.2 Hairpin oligo sequences
Oligo name Sequence
miRNA_ENL.l TGC TGT TGA CAG TGA GCG CGC GAG AAG CTC ACC TTC AAC ATA GTG A AG
CCA CAG ATG TAT GTT GAA GGT GAG CTT CTC GCA TGC CTA CTG CCT CGG A 
miRNA_ENL.2 TGC TGT TGA CAG TGA GCG AGC AAA GAC TCC GAG AGC AAG ATA GTG AAG
CCA CAG ATG TAT CTT GCT CTC GGA GTC TTT GCG TGC CTA CTG CCT CGG A 
miRNA_ENL.3 TGC TGT TGA CAG TGA GCG AGC CAC TTC AAT GTC ACC AAC ATA GTG AAG
CCA CAG ATG TAT GTT GGT GAC ATT GAA GTG GCC TGC CTA CTG CCT CGG A 
m iRNA_m LM 02_2 TGC TGT TGA CAG TGA GCG ACC CAC AGA TTG TTT CTA TAC ATA GTG AAG 
CCA CAG ATG TAT GTA TAG AAA CAA TCT GTG GGG TGC CTA CTG CCT CGG A 
m iRNA_m LM 02_4 TGC TGT TGA CAG TGA GCG CTG GAC TAG AGTGT GCA ATT ATA GTG AAG
CCA CAG ATG TAT AAT TGC ACA ACT CTA GTC CAT TGC CTA CTG CCT CGG A 
miRNA_HLF_l TGC TGT TGA CAG TGA GCG CGC AAG AAC ATA CTT GCC AAG TTA GTG AAG
CCA CAG ATG TAA CTT GGC AAG TAT GTT CTT GCA TGC CTA CTG CCT CGG A 
miRNA_ HLF _2 TGC TGT TGA CAG TGA GCG CGA ACA TAC TTG CCA AGT ATG ATA GTG AAG
CCA CAG ATG TAT CAT ACT TGG CAA GTA TGT TCT TGC CTA CTG CCT CGG A 
miRNA_ HLF _3 TGC TGT TGA CAG TGA GCG CGG GCA AGG CGC AGA A AG AAC ATA GTG AAG
CCA CAG ATG TAT GTT CTT TCT GCG CCT TGC CCA TGC CTA CTG CCT CGG A 
miRNA_ HLF _4 TGC TGT TGA CAG TGA GCG CGG AGC TGG GCA AAT GCA AGA ATA GTG AAG
CCA CAG ATG TAT TCT TGC ATT TGC CCA GCT CCT TGC CTA CTG CCT CGG A
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Table 2.3 PCR primers
Primer name Sequence
pSM2C Forward 5 '-GAT GGCT G-CTCG AG-AAGGTATAT-T GCT GTT G AC AGT G AGCG-3'
pSM2C Reverse 5'-GTCTAGAG-GAATTC-CGAGGCAGTAGGCA-3'
EFl-a Forward 5 '-G AAT GC ATA ATT GGCTCCGT GCCCGTC-3'
EFl-a Reverse 5 '-CT GCTAGCTC ACG AC ACCT G AAAT GG A AG-3'
Table 2.4 Sequencing Primer for shRNA
Primer name Sequence
pSM2sequencing 5'-ACAGAATCGTTGCCTGCACA-3'
2.3.13. DNA sequencing for shRNAs
The samples for performing cycle sequencing were prepared by mixing 1.5 pi of DMSO, 1 
pi of primer (3.2 pmol, Table 2.4), 6pl of Terminator Ready Reaction Mix (Applied Biosystems), 
and 6.5 pi of DNA (200-500ng) to give a final volume of 15 pi per reaction.
The conditions used to sequence DNA were 25 cycles of 94 °C for 30' sec, 50 °C for 15 sec 
and 60 °C for 4 min. Following this, the extension products were purified. Briefly, each 
extension reaction was mixed with 80 pi of 75% isopropanol in 1.5 ml microcentrifuge tube and
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left at room temperature for 15 min to precipitate the extension products. They were then spun 
for 20 min at maximum speed and the supernatants were aspirated carefully. 250 pi of 70% 
ethanol was added to the DNA pellets and were then washed by spinning for 10 min at maximal 
speed. Supernatants were carefully aspirated, allowed the samples to dry. The sample pellets 
were suspended in 3 pi of sequencing loading buffer (containing deionised formamide and 
EDTA with blue dextran at 5:1 ratio), and heated at 100 °C for 2 min before carrying out sample 
electrophoresis. Please refer to the manufacturer’s instructions for the detailed protocol.
2.4. T ra n s d u c tio n  o f  H a e m a to p o ie tic  C e l ls
2.4.1. Lentivirus generation and harvesting
The evening before transfection, 293 FT cells were subcultivated and plated in a 10 cm 
tissue culture dish such that they could be transfected at 90% to 95% confluency (i.e. 4 x 10 6 
cells in 10 ml of growth medium containing serum). On the morning of the day of transfection, 
culture medium was removed from the 293 FT cells and was replaced with 5ml of appropriate 
growth medium supplemented with serum, but no antibiotics was contained. In the evening, 
transient transfections in 293 FT cells were carried out using the thee-plasmid system with 
Lipofectamin 2000 (Invitrogen) transfection reagent. For each transfection sample, 
DNA-Lipofectamine 2000 complexes were prepared by gently mixing 5 pg of transfer vector 
(viral plasmid), 3.75pg of packaging plasmid (psPAX2; a gift from Trono Didier, Laboratory of
Virology and Genetics, Switzerland) and 1.5pg of envelope plasmid (pMD2G; a gift from Trono
Didier, Laboratory of Virology and Genetics, Switzerland) with 1.5 ml of Opti-MEM medium 
{Invitrogen). In a separate sterile tube, 30 pi of Lipofectamine 2000 was diluted in 1.5 ml of 
Opti-MEM medium without serum, and was gently mixed and incubated for 5 min at room 
temperature. Following this, diluted DNA with the diluted Lipofectamine 2000 were combined 
and gently mixed. DNA-Lipofectamin 2000 mix was then incubated at room temperature for 20
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min at room temperature to allow the DNA Lipofectamine 2000 complexes to form. 3ml of 
DNA-Lipofectamine 2000 complexes were added drop-wise to each plate of 293 FT cells and
incubated overnight at 37 °C/5% CO2 incubator, the next day, medium containing the
DNA-Lipofectamine 2000 complexes were removed and replaced with complete culture medium 
containing sodium pyruvate, providing energy for viral production. At 48 h post-transfection, 
virus-containing supernatants were harvested and cleared of cellular debris by low-speed 
centrifugation (1200 rpm for 5 min at 4°C). Viral particles were filtered through 0.45pm 
membrane and concentrated using Centricon® Plus-70 unit 10-fold by centrifugation at 1500 
rpm at 15 °C for 30-45 min and resuspended in 2 ml of DMEM medium containing 10% FCS, 2 
mM, L-glutamine and 100 U/ml penicillin 100 pg/ml streptomycin.
2.4.2. Lentivirus infection and titreing
To establish knockdown efficiency, immortalised MLL-ENL and primary immortalised 
LM02/BCL2 and E2A-HLF haematopoietic progenitor cells were cultured in a 6-well plate in 
medium containing recombinant murine cytokines for 24 h prior to infection. For lymphoid cell 
assays, cells were cultured in DMEM medium containing 10% FCS, 2mM, L-glutamine, 100 
U/ml penicillin 100 pg/ml streptomycin, 50 pM 2-ME withlOO ng/ml stem cell factor (SCF), 200 
ng/ml IL-7 and 10 ng/ml fm s-like tyrosine kinase-3 ligand (Flt-3-L). For myeloid assays, cells 
were cultured in DMEM medium containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 
100 pg/ml streptomycin with 100 ng/ml SCF, 10 ng/ml IL-3 and 10 ng/ml IL-6.
Infections were performed in 96-well plates (1 x 104 cells/100 pl/well) with concentrated 
lentivirus resuspended in DMEM medium containing 5 pg/ml polybrene (Sigma), 20% FCS, 
L-glutamine, 100 U/ml penicillin, 100 pg/ ml streptomycin, 50 pM 2-ME and appropriate 
cytokines. Presence of polybrene during virus adsorption enhanced transduction by acting as a
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small neutraliser that binds to the negatively charged cell surfaces and thus allows the viral 
glycoproteins to bind more efficiently to their receptors by reducing the repulsion between sialic 
acid-containing molecules. HPCs were spininfected by centrifugation at 1800 rpm at 25 °C for 
45 minutes. Fresh medium containing appropriate cytokines was added to infected cells 24 h 
after infections.
To achieve maximal infection efficiency, MOI (Multiplicity Of Infection = ratio of 
infectious virus particles to cells) was approximated by titreing different viral supernatants on 
BAF3 by 5 fold serial dilutions while SEM2K, 32D, Cl 1 and LM02/BCL2 cells were infected, 
by serial dilutions, with the same virus. MOI was estimated from mathematical calculation 
and line graph.
2.5. F lu o re s c e n c e  A c tiv a te d  C e l l  S o r t in g  (FACS) A n a ly s is  o f  T ra n s d u c e d  C e l ls
2.5.1. eGFP expression analysis
Transduced cells were removed from the flat-bottom 96 well plate to the conical-bottom 96 
well plate and were then washed with PBS by centrifugation for 5 min at 1200 rpm. Following 
the removal of PBS, the transduced cells were resuspened in FACS buffer (Table 2.1) in the 
FACS tubes. FACS was performed using Beckman-Coulter Epics ALTRA flow cytometer and 
expression of eGFP was analysed using accompanying software, which revealed percentage of 
GFP positive cells, mean fluorescence intensity (MFI) of the GFP positive cell population and 
cell viability. Appropriate uninfected controls were used for all FACS analyses.
2.5.2. eGFP-positive transduced cell sorting
The transduced cells were collected in the FACS tubes, and suspended in the FACS buffer 
before carrying out cell sorting analyses using DakoCytomation CyAn ADP flow cytometer. The 
infected cells were separated from the uninfected cells and were collected according to the
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expression of GFP. The eGFP-positive cells ( lx l0 6 cells) were plated and grown in the 
appropriate medium.
2.6. D e t e c t io n  o f  P r o t e in  e x p r e s s io n  l e v e l
2.6.1. Protein assay
BSA (Promega) was used to prepare serial 1:2 dilution of protein standard starting from 10 
pg/pl to 0.156pg/pl. 2 pi of protein sample or protein standard was added to 500 pi of 1 X 
BIoRad protein assay reagent in each 1.5 ml tubes. 150 pi of mixture was transferred into a well 
of a 96-well microtitre plate. Absorbance was measured at 595 nm and proteins were 
quantified using BioRad GS-800 densitometer and software.
2.6.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Cells were centrifuged at 1200 rpm for 5 min at 4 °C to remove the medium, then washed 
twice in cold PBS and lysed in RIPA lysis buffer (Table 2.1) containing protease inhibitors 
{Roche). Cells were transferred into a 1.5 ml tube and left on ice for 30 min before another 
centrifugation at 13.2 k rpm for 10 min at 4°C to remove the cellular debris. Supernatant were 
transferred into a fresh tube and stored at -20 °C for short term storage or at -80°C for long term 
storage.
Protein concentration of cell lysates was determined from the protein standard curve by 
protein assay. To prepare sample for SDS-PAGE, appropriate amount of lysis buffer was added 
to 10 pg protein from the cell lysate to give a final volume of 10 pi, mixed with an equal volume 
of 2X sample buffer (Table 2.1). Samples were boiled for 5 min at 100°C before loading on to 
a SDS-PAGE gel.
Cell lysates containing lOpg protein was resolved by electrophoresis in 10% SDS-PAGE 
gels. SDS-PAGE was carried out using Mini Protean III apparatus (.BioRad) according to
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manufacturer’s instructions. 10% resolving gels contained 10% acrylamide (National 
Diagnostics, Atlanta, Georgia, USA), 375 mM Tris-HCI (pH 8.8), 0.1% SDS, 0.1% ammonium
persulphate (Sigma) and 0.4% N, N, N', N'-tetramethylethylenediamine (TEMED) (Sigma).
Stacking gels contained 5% acrylamide, 125 mM Tris-HCI (pH 6.8), 0.1% 55 SDS, 0.1% 
ammonium persulphate and 0.1% TEMED. Gels were electrophoresed in SDS-PAGE 
electrophoresis buffer (Table 2.1) at 80 V.
2.6.3. Protein transfer to polyvinylidenefluoride membrane (PVDF)membrane
Proteins in SDS-PAGE gels were transferred on to PVDF membrane (Millipore) in protein 
transfer buffer (Table 2.1) using a BioRad Mini Trans-Blot Electrophoretic Transfer system 
according to the manufacturer’s instructions. Gels were transferred for 1 h 100 V.
2.6.4. Western blotting analysis
All antibodies were diluted in 5% milk powder in TBS-T (Table 2.1). Working dilutions of 
antibodies used for Western blotting analysis are given in Table 2.3. Membranes were incubated 
for 1 h at room temperature with gentle agitation in 5% milk powder in TBS-T. Blocking 
solution was discarded. Membranes were subsequently incubated with primary antibody (Table 
2.5) for 1 h at room temperature with gentle agitation. Membranes were washed in TBS-T for 
three 10 min washes with agitation at room temperature. Membranes were subsequently 
incubated for 1 h with the relevant secondary antibody (Table 2.5) with agitation at room 
temperature. Membranes were washed as previously described followed by a final 5 min wash 
with TBS buffer (Table 2.1). Membrane was washed once for 5 min at room temperature with 1 
X TBS. Enhanced Chemiluminescence (ECL™) reagent (Amersham Biosciences, Little Chalfont, 
UK) was prepared by mixing an 1 ml of solution A to an equal volume of solution B. Excess 1 X 
TBS was drained off from membrane and the protein-side was placed down on to ECL™ reagent,
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left for 1 min. Excess ECL™ reagent was drained off from membrane, which was then 
wrapped in fresh cling film and placed in a film cassette. Proteins were visualised by ECL™ 
reagent when exposed to film and developed in the dark room.
Table 2.5 Antibodies Used for Western Blot Analysis
Antibody Manufacture Isotype Working solution
Mouse anti-p Actin Santa Cruz Biotechnology IgG 1:1000
Mouse anti-Myc 9B11 Santa Cruz Biotechnology IgG 1:1000
Rabbit anti-Hsp90 Santa Cruz Biotechnology IgG 1:2000
Donkey anti-mouse-HRP conjugate Santa Cruz Biotechnology IgG 1:2000
Donkey anti-rabbit-HRP conjugate Santa Cruz Biotechnology IgG 1:2000
2.7. D e t e c t io n  o f  mRNA e x p r e s s io n  le v e l
2.7.1 Isolation of total RNA
Total RNA was extracted from 5 x 105 cells using RNeasy® Mini Kit (Qiagen) following 
the recommended manufacturer’s procedure. Briefly, pelleted cells were lysed in 600 pi buffer 
RLT and the lysate was transferred into a QIAshredder spin column placed in a 2ml collection 
tube and centrifuged for 2 min at full speed. 1 volume of 70% ethanol was added to the 
homogenised lysate, it was then spun through the RNeasy spin column for 15s at 10,000 rpm. 
After flow through was discarded, 700 pi Buffer RW1 was added to the column to wash the 
membrane by centrifugation for 1 min at 10,000 rpm. RNA was eluted in 30-50 pi RNase-free 
water by centrifugation for 1 min at 10,000 rpm and stored at -80 °C until use.
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2.7.2 Detection of E2A-HLF and GAPDH transcripts by reverse transcriptase-quantitative 
PCR (RT-qPCR)
RT reaction was set up by mixing 10 pg RNA, 2 pi DNase 1 enzyme, 2 pi DNase buffer 
(xlO) and DEPC water was added to make up a total volume of 40 pi. The mixture was incubated 
at room temperature for 15 min. To stop the reaction, the mixture was added with 2 pi of 25 mM
EDTA and incubated at 65 °C for 5 min then placed on ice. To perform cDNA synthesis, 8 pi
first strand buffer (x5, Invitrogen), 4 pi DTT {Invitrogen), 2 pi random primers (0.32 pg/pl, 
Invitrogen), 2 pi dNTP (10 mM for each dNTP, Invitrogen), 2 pi RNase Out {Invitrogen), 2 pi
MMLV-RT {Invitrogen) were added to the RT reaction mixture and first incubated at 37°C for 2
h then at 70°C for 15 min. Control tubes contained all of the reagents for cDNA synthesis except 
RT.
To conduct q-PCR, 5 ng of total cDNA was used in 20 pi per PCR reaction (in 
MicroAmp™ Fast Optical 96-Well Reaction Plate, Applied Biosystem) containing 10 pi of lx 
TaqMan(R) Fast Universal PCR Master Mix {Applied Biosystem) and lpl of the primer either 
amplifying LM02 or GAPDH {Applied Biosystem), using 7900HT Fast Real-Time PCR machine. 
A negative control contained no template DNA was included to make sure there was no RNA or 
DNA contamination to the qPCR reagents. GAPDH was used as a reference gene. Cycling 
conditions were 95 °C for 20 sec followed by 40 cycles of 95 °C for 1 sec and 60 °C for 20 sec.
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2.7.3 Calculation of LM02 mRNA expression levels relative to the GAPDH housekeeping 
gene
The calculation was based on the assumption that the level of expression of the reference 
molecule (GAPDH gene) must not vary under the different experimental conditions being 
studied. This level was used as a reference value for quantification. qPCR Ct value is the point 
where the growth curve crosses the threshold, reflecting the amounts of cDNA produced by the 
reverse transcriptases, with total RNA from the cells.
Relative quantification (ratio between the amount of LM02 and GAPDH molecules) was 
determined by the following equations:
1) Cttarget -  CtGAPDH = ACti 2)ACti-ACtcontroi =AACt 3)2'aaQ = relative expression level
44
CHAPTER 3  
RESULTS
3.1 L o w -E x p re s s io n  A c t iv ity  o f  CMV p ro m o te r  in  H a e m a to p o ie tic  C e l ls
The construction of basic vector p201 (a gift from Stephen J. Elledge, Appendix 1) of 
pPRIME (potent RNAi using iR expression) series has been previously described (Stegmeier, Hu, 
Rickies, Hannon, & Elledge 2005). Lentiviral vector p201 is of “minimal lentiviral genomes” 
containing RRE, cPPT and woodchuck hepatitis virus posttranscriptional regulatory (WPRE) 
elements, in the other words, dispensable lentiviral virulence/accessory genes have been 
eliminated. During transcription of HIV, the RRE sequence is bound by the viral Rev, an 
essential HIV-1 regulatory protein, tethering the viral RNA to the CRM 1-mediated nuclear 
export pathway. In the absence of Rev or RRE the genomic RNA of HIV is either spliced or 
degraded and does not efficiently reach the cytoplasm, a prerequisite for packaging (Cullen 1998). 
WPRE and cPPT elements are downstream from the transgene in an effort to increase nuclear 
export and to provide high gene expression levels in haematopoietic cells (Demaison et al. 2002). 
U3 region of the 3’ LTR is deleted to improve the safety of the vector system. The vector also 
contains eGFP marker gene driven by an internal promoter CMV. To optimise gene 
knockdown effectiveness, primary microRNA transcripts, which are endogenous triggers of 
RNAi, has been included in the vector. miR30 was chosen because processing of the larger 
pre-miRNA transcript (70 nt) to its functional miRNA has been well characterised in vitro and in 
vivo (Cullen 2004).
To investigate the CMV promoter activity of p201 vector, 293FT cells were transfected with 
this viral vector together with the relevant packaging and envelop plasmids to produce the virus 
carrying CMV promoter. psPAX2 packaging construct (kindly provided by Didier Trono, 
Appendix 2) expresses gag, pro and pol, which encode the structural proteins as well as the 
enzymes (reverse transcriptase, RNase H, integrase and protease), tat, rev and vpu responsible 
for increasing virus production are also expressed (Logan, Lutzko, & Kohn 2002;Tang, Kuhen, 
& Wong-Staal 1999). pMD2G envelop construct (kindly provided by Didier Trono, Appendix 3)
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expresses vesicular stomatitis virus glycoprotein (VSV-G) that confers the viral particle with the 
stability to transduce a broad range of cell types, including primary cells and stem cells (Logan, 
Lutzko, & Kohn 2002;Tiscomia et al. 2003). Primary immortalised haematopoietic cell lines, 
primary HSCs in myeloid and lymphoid conditions as well as immortalised haematopoietic cell 
line (BAF3) were then infected and analysed for eGFP expression by fluorescent microscopy 3 
days (Figure 3.1) and by FACS 3 days, 7 days after infection (Figure 3.11, 3.12). Uninfected 
cells were used as a negative control, so that the strength of CMV promoter in the infected cells 
could be quantitatively determined by FACS analysis by measuring the level of eGFP reporter 
gene expression (MFI). When the CMV promoter activity was examined under the inverted 
fluorescence microscopy, eGFP expression, of different intensity, was detectable in many 
infected cell whereas no fluorescent cells were observed in the negative control cells, proving 
that this vector was functional in the haematopoietic cells.
However, fluorescence microscopy lacked of providing the precise information on the 
promoter activity and transduction efficiency. Thus, FACS analysis was carried out. Using an 
eGFP marker transgene under the transcriptional control of a CMV, the level of transduction as 
determined by the gating has achieved 85.5% on average in the input cells at 3 days 
post-infection, confirming that high efficiency of transduction of the haematopoietic cells, even 
the hard-to-transfect primary cells and HSCs, was feasible using 2nd generation of HIV-1-based 
lentiviral vector. As expected, well-established haematopoietic cell line (BAF3) was most 
infectable which also showed relatively high gene expression in comparison to the primary 
haematopoietic cell lines. Nevertheless, the gene expression levels in all the transduced cell lines, 
including BAF3 cells were considerably low. Furthermore, MFI on an average of 22 in the input 
cells has further reduced by 36% at 7 days post-infection, suggesting that the gene expression 
driving by CMV promoter was not only undesirable but also rather unstable in the 
haematopoietic cell lines. Altogether, the activity of internal CMV promoter has proven to be
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short-termed and weak in haematopoietic cell lines in vitro, although this is one of the most 
popular promoters that has been used to over-express foreign genes in many different cell lines, 
revealing a cell specificity of the CMV promoter activity. Thus, there was a need to replace 
CMV promoter with an alternative promoter that could drive strong and long-term expression in 
haematopoietic cell and thereby to allow a more effective gene knock-down in the 
haematopoietic cells.
Figure 3.1 Analysis of eGFP expression of p201CMV in haematopoietic cell lines by 
inverted fluorescence microscopy
Uninfected haematopoietic 
cells, 3 days after infection
Infected haematopoietic 
cells, 7 days after infection
eGFP Images
eGFP images show the detection of eGFP expression in the cells transduced with p201CMV 
lentiviral vector whereas no fluorescent cells are visible in the uninfected control cells.
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3.2 R e p la c e m e n t o f  CM VP ro m o te r  w ith  SF FV P ro m o te r
As suggested from the previous experiment, lentiviral vectors p201 using an internal CMV 
promoter to transcribe the gene was not yet optimised for efficient expression in haematopoietic 
cells. It was then aimed to replace CMV promoter with an alternative one to achieve long-term 
expression in (primary) haematopoietic cell lines. It has been shown that significantly higher 
levels of GFP expression (3- to 5-fold) were achieved with E F la promoter than that of CMV 
promoter in the human haematopoietic stem/progenitor cell (HSPC) line KG la  (Ramezani, 
Hawley, & Hawley 2000), unfortunately, cloning of this promoter was unsuccessful. Efficient 
transduction by spleen focus forming virus (SFFV) promoter in haematopoietic repopulating 
cells has been reported (Demaison, Parsley, Brouns, Scherr, Battmer, Kinnon, Grez, & Thrasher 
2002).
Cloning strategy for the replacement of CMV promoter by SFFV involved blunting. Due to 
the limitation of enzyme recognition sites available in the vector, the more effective sticky-ended 
ligation followed by double digestion was thus not employed. A unique EcoRI site at position 
7749 in the donor vector (CSGW) and Xbal site at position 2576 in the recipient vector (p201) 
were blunted. Thus, the EcoRI site in the basic p201 vector remained unique and available for 
the subsequent cloning of shRNA. Different cloning strategies have been employed, and the 
resultant construct was obtained by the strategy described as follows (Figure 3.4).
5pg of vector p201 was restriction digested in a total volume of 100 pi for 2 hours with 5% 
of Xbal enzymes (Figure 3.2, Figure 3.4 stage A). 5’end overhangs produced from Xbal
enzyme cleavage were then incubated with Large Klenow Fragment to generate blunt ends by 
filling in recessed 3’ends of DNA fragments. The linearised vector with blunt ends was further 
digested with Notl enzyme, resulted in two DNA fragments, 1.35 kb and 7.15 kb (Figure 3.3, 
Figure 3.4 stage B), that both consisted of one sticky and one blunt end. The vector DNA 
upon the removal of CMV promoter and eGFP transgene was recovered after gel purification of
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the 7.15 kb hand, using the Qiagen MinElute Gel Extraction kit and stored at -20°C.
8.5 kb
850
Figure 3.2- Digest of p201 
with Xbal.
Lane 1: sample 
Land 2: ladder marker
Figure 3.3- Digest of p201 
with Notl.
Lane 1: ladder marker 
Lane 2 & 3: sample 1, 2
7.15 kb 
1.35 kb
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Figure 3.4-CIoning Strategy for Changing of the Promoter (not drawn in scale)
CSGW Vector p201 VectorStage A)
EcoRI Notl Xbal Notl
LTR CMV eGFP miR30eGFP LTR LTRLTR SFFV
Digest with EcoRI Digest with Xbal
5’ overhangs fill-on 5’ overhangs fill-on
Stage B)
Blunt BluntBlunt Blunt
SFFV eGFP LTR LTR CMV eGFP miR30LTR LTR
Digest with Notl
Digest with Not!
Gel Purification
Gel Purification
Stage C)
Blunt Notl Blunt Notl
eGFP LTRSFFV LTR
Ligation
Stage D)
SFFV eGFP miR3LTR LTR
p201 SFFV Vector
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The SFFV element to be inserted into the linearised p201 construct was recovered from 
another vector, CSGW, (see Appendix 4). Vector CSGW is a self-inactivating HIV-1 
packageable vector, encodes eGFP expressed from a SFFV 5'LTR promoter. A unique 
endonuclease-EcoRI site within the SFFV promoter sequence was eliminated by cutting (Figure
3.5, Figure 3.4 stage A), filling in with Large Klenow Fragment. The linearised vector was then 
cleaved by Notl enzyme (Figure 3.4 stage B), which gave rise to two bands appearing on the 
agarose gel, one at 1.3 kb and one at 8.4 kb (Figure 3.6). The SFFV element fused with eGFP 
open-reading frame was recovered after gel purification of the 1.3 kb band, using the Qiagen 
MinElute Gel Extraction kit.
.7 kb 8.4 kb 
1.3 kb
Figure 3.5- Digest of CSGW vector 
with EcoRI.
Lane 1: ladder marker 
Lane 2: sample
bp
1 2 , 0 0 0
1 , 6 5 0
Figure 3.6- Digest of CSGW vector with Notl. 
Lane 1 & 2: sample 1, 2 
Lane 3: ladder marker
The recovered insert and vector p201 were then ligated (Figure 3.4 stage C) for 2 hours at 
room temperature according to the following vector/insert molar ratios: 1:3, 1:0. The ligation 
products were then transformed into competent E.coli cells. The transformation cultures were
spread on to the gel plate containing ampicillin and were incubated overnight at 37°C. Colonies 
were picked the next morning and grown overnight at 37°C in 5ml of LB medium containing
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ampicillin. The DNA was extracted from the cells when the bacteria were at the exponential 
growth phase. A series of diagnostic digests was performed in order to identify which clones 
contained the desired vector. Each of the extracted DNA samples were first restriction digested 
with two combinations of restriction enzymes, EcoRI/Xbal and Notl/BamHI, which was able to 
tell us whether the blunting reaction by Large Klenow Fragment worked and whether the ligation 
was successful. Since there should be no Xbal site present in the recombinant vector after 
blunting and only one EcoRI site in the vector backbone, clone 2, 5, 10, 13 and 14 that showed 
single band seemed to be promising (Figure 3.7). Nevertheless, appearance of single band on the 
gel after EcoRI/Xbal digestion could also indicate an empty vector, thus Notl/BamHI digestion 
was carried out as empty vector did not have BamHI cutting site while recombinant vector did. 
Two bands, one at 7758 bp and the other at 742 bp, were expected from Notl/BamHI digestion as 
Notl cut once at position 3825 and BamHI is the unique site at position 3084 within the insert 
part (Figure 3.8.). By combining the results from EcoRI/Xbal and Notl/BamHI digests, clone 14 
appeared to be the only clone that contained the right vector. Clone 14 was then further 
subjected to several diagnostic digests with BamHI/EcoRI, BamHI/Xbal, Nhel/EcoRI and 
Nsil/Ecorl to make sure this was the desired vector for later cloning. As expected, two bands 
showed on the gel from the BamHI/EcoRI (Figure 3.9), Nhel/EcoRI and Nsil/EcoRI digests 
(Figure 3.10) while only one digested band showed from the BamHI/Xbal digest (Figure 3.9). 
DNA sequencing analysis has verified sequence of this vector. The new vector generated was 
named p201SFFV (Figure 3.4 stage D).
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
7 kb M S 8.5 kb
1.5 kb-
Figure 3.7- Digest of miniprep DNA with EcoRI and Xbal to eliminate the clones that definitely 
have undestroyed EcoRI and Xbal sites.
Lane 1-3, 5-10, 12-17: sample 1 to 15 
Lane 11, 19: ladder marker
Figure 3.8- Digest of miniprep DNA with BamHI and Notl to eliminate the 
clones that definitely have no inserts.
Lane 1-3, 6-17: sample 1-15 
Lane 4,5, 18: ladder marker
7758 bp 
742 bp
54
7605 bp 
895 bn -
7604 kb' 
.8.5 kb
896 kb ~
Figure 3.9- Digest of DNA from 
clone 14 with BamHI/EcoRI 
(lane 1) and BamHI/Xbal (lane 3). 
Lane 1,3: sample 1, 2 
Lane 2: ladder marker
7012 bp
1488 bp
Figure 3.10- Digest of DNA from clone 
14 with Nhel/EcoRI (lane 1) and 
Nsil/EcoRI (lane 3).
Lane 1, 3: sample 1, 2 
Lane 5: ladder marker
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3 .3  H ig h -L e v e l T ra n s d u c tio n  a n d  L o n g -T erm  G ene E x p re s s io n  in H aem ato p o ie tic  
C e l ls  U sing 2nd G e n e ra tio n  o f  L e n t iv ir a l  V e c to r  p201 in c o rp o ra t in g  S F F V  
P ro m o te r
Following the successful cloning of SFFV promoter into p201 vector in replacement of 
CMV promoter, the effect of the SFFV promoter on transgene expression in haematopoietic cells 
in vitro was then evaluated using FACS analysis. The virus bearing p201SFFV expression 
cassette was used to transduce primary immortalised cell lines (E2A-HLF, MLL-ENL, and 
LM02/BCL2), primary haematopoietic cell lines (myeloid and lymphoid conditions) and 
established haematopoietic cell line (BAF3). Uninfected cells were used as the negative 
controls. The efficiency of transcription of the eGFP reporter gene from p201SFFV lentiviral 
vector after stable incorporation into the target cell genome was measured 3 days and 7 days 
after infection, as illustrated in Figure 3.11. The levels of eGFP reporter gene expression 
from the transduced cells were directly examined for the efficiency of transcription after stable 
integration into the host genome. It is shown that the levels of eGFP reporter gene expression of 
all the haematopoietic cells transduced with p201SFFV at 3 days post-infection were 
exceptionally high compared to that of p201CMV-transduced cells and the transduction 
efficiency was almost 100% as determined by the gating. Percentage of eGFP-positive cells 
stayed constant at 7 days post-infection, MFI values have significantly increased in all the 
transduced cells (Figure 3.13). Highest MFI was observed in BAF3 cell line, which was of 2-4 
folds more than that of primary haematopoietic cells. The result (Figure 3.11, 3.12, 3.13) 
demonstrated that the newly derived vector p201SFFV not only enhanced gene transfer 
efficiency, as measured by the percentage of eGFP-positive cells, but also showed greatly 
improved stability of gene expression, as measured by the MFI of eGFP, over the parent vector 
p201CMV in the infected cells. The result definitely suggested that SFFV promoter can induce
56
long-term gene silencing in a variety of haematopoietic cells, including primary and 
non-dividing HSCs in vitro.
Figure 3.11. Comparison of transduction efficiency and gene expression between p201 
CMV and p201 SFFV by FACS analysis
2nd Generation p201CMV
miR30-based shRNA
I
CMV eGFP
2nd Generation p201SFFV
SFFV
miR30-based shRNA
I
eGFP
Infection o f  H aem atopoietic Cells (BA F3)
2 *  G  n
3 3* cr
2 < i  nn©ss
133-
99-
i
; 66 -
I
33-
0
p201C M V p201SFFV
ISO-
|R5 97- |R5
95% ( 1 0 0 %
- i  6 5 _ A i
J L  MFI=35 32-
M F I= 5 4 0 J|
— j m L — T— o- ------------ »-------------- t—
10°  10 ' 102 
* eGFP
103 10 * 10° 101 102
315 267-
M57- ■133-
MFI=21
R5
3 Days
103 10*
100%
MFI=8598
7 Days
10°  10 ' 103 10* 10°  10 ' 102 103 10*
57
Relative 
count
Infection o f  E2A -H L F Prim ary Im m ortalised  C ells
p201C M V p201SFF V
100%
MFI=12 MFI=516
9 6 -
7 2 -
4 8 -
2 4 -
10°
|R 5
A
V h l :
89%
MFI=14
10 ' 102 
* eGFP
103
2 4 0
1 8 0  —I
j 1 2 0 “
10* 10°
100%
MFI=2187
6 0 -
Infection o f  L M 02/B C L 2 Prim ary Im m ortalised  C ells
1 8 3  
1 3 7
i 91
I
4 5  
0
1 0 °  1 0 '  1 0 2 1 0 3 1 0 *  1 0 0  1 0 i 1 Q 2  1 0 3 1 0 i
P
MFI=14
2 4 0
0 
10°
2 4 0 - r
R 5
- 53% 1 8 0 -
IL j 1 2 0 “ 
1
J MFI=12 6 0 -o-
1 0 '  102 103 10*
MFI=182
J k
3 Days
7 Days
3 Days
7 Days
58
Relative count
Infection o f  M LL -E N L Prim ary Im m ortalised C ells
p201C M V p201SFFV
109
MFI=912
MFI=24
102 103 10*
252-
189-
126-
63-
10° 10 ' 102 
eGFP
252-
|R5
2 0 %
189-
1
i 4 Oft —
|R5
ALL MFI=12r i | 1 ZOi 63-o -A
103 10* 10°  101 102 103 10*
162-
121 -  
| 81-  
40-
Infection o f  Prim ary H SC s in Lym phoid C ondition  
p201C M V  p201SFFV
162-
|R5
▲
85%
MFI=24
0° 10 '  102 103
MFI=171
102 103 1 0 *
234
100%
*117- ■ 1 2 2 -
MFI=1480
MFI=8
10' 102 1 o3 1 0 1 102  1 0 3 1 0 *
3 Days
7 Days
3 Days
7 Days
59
Infection o f  Prim ary H SC s in M yeloid C ondition
MFI=912
MFI=24
j
3 Days
102 103 10*
660-
495-
3C
3o*A
50 !«  ; 330-
165-
0 
10°
165-
|RS 50% 123- |RS g 2 „/o
| 8 2 -
A
MFI=18 MFI=2680
41 - ■
______ o - . .
101 
+  eGFP
102 103
7 Days
10* 10° 10 ' 102 103 10*
Fig 3.11 Analysis of eGFP expression of p201CMV and p201SFFV in haematopoietic cell 
lines. p201CMV shows low-level and short term expression whereas p201SFFV shows 
high-level and long term expression in primary HSCs, primary immortalised haematopoietic cell 
lines and established haematopoietic cell lines. Transduction efficiency is enhanced in the cells 
transduced with p201SFFV lentiviral vector in comparison to that with p201CMV vector.
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Figure 3.12
CMV prom oter activity ag a in st haem atopoietic cell 
lines
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CMV promoter drives low-level gene expression in the transduced cell 
lines. Gene expression decreased 7 days after infection.
Figure 3.13 SFFV prom oter activity ag a in st haem atopoietic cell 
lines
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SFFV promoter drives high-level gene expression in the transduced cell 
lines, in BAF cell line in particular. Gene expression significantly 
increased 7 days after infection.
3.4. C lo n in g  o fs h R N A s  in to  L e n t iv ir a l  V e c to r  SFFVp201
Once long-term expression of lentiviral vector SFFVp201, derived from parent p201, has 
been confirmed by FACS analysis, construction of shRNA lentiviral vectors was completed by 
subcloning of the candidate shRNA oligo into p201SFFV vector. A selection of the shRNA 
target sequences (Table 2.2) were designed, by The BLOCK-iT™ RNAi Designer from 
Invitrogen website and RNAi Central shRNA Designer from Hannon’s lab 
(http://katahdin.cshl.org:9331/siRNA/RNAi.cgi?type=shRNA) , against the candidate leukaemic 
fusion genes, include human MLL-ENL and human E2A-HLF as well as LM 02 mouse gene that 
was found to be abnormally up-regulated by transcriptional fusion protein E2A-HLF in 
leukaemic cells. Generally, at least 3 different oligos need to be generated and tested for every 
target gene as a success rate of one in three was seen in most experimental settings. A number 
of design criteria have been recommended to construct effective shRNA expression vectors. The 
target sequence should be 21-23 bases long while longer molecules can trigger a PKR (protein 
kinase activated by dsRNA) response. The G/C content should be 40-55%, also stretches of 
four or more nucleotide repeats and targeting introns should be avoided. Furthermore, to prevent 
the off-target effects, database search was performed to filter out the sequences that share a 
certain degree of homology with other related or unrelated genes, avoiding silencing of these 
loci.
To clone the hairpin insert into vector SFFVp201, they were first amplified from the oligos 
by PCR with low cycle numbers to minimise the chance of having mutation in the resultant 
products. pSM2C primers (Table 2.3) were used to perform amplification of all the shRNAs. 
The forward primer for amplifying the siRNA sequences incorporated Xhol restriction site also 
overlapped with the beginning of miR30 sequence while the EcoRI restriction site and last few 
bases of miR30 sequence were contained in the reverse primer. To accomplish the final step of 
construction of miR30-based shRNA lentiviral vectors, PCR products (110 bp) were first
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digested with EcoRI and Xhol enzymes for 4 hours at 37°C, and then directly cloned into 
well-digested vector p201SFFV (Figure 3.14) flanked by the corresponding recognition sites. 
Presence of hairpin insert in the p201SFFV was checked on the 2% agarose gel by diagnostic 
digesting with Xhol and EcoRI enzymes. The result from diagnostic digest (Figure 3.15) 
indicated that all the clones contained the right vectors as a small band at 110 bp and one vector 
DNA band at 8.5 kb were revealed in each sample. The shRNA sequences have been confirmed 
by sequencing analysis. The newly generated shRNA plasmids (Appendix 5) were named 
p201 SFFV-miR30-MLL, p201 SFFV-miR30-ENL 1, p201 SFFV-miR30-ENL2, p201SFF V- 
miR30-HLFl, p201SFFV-miR30-HLF2, P201SFFV-miR30-HLF3, P201SFFV-miR30-HLF4, 
p201SFFV-miR30-LM02.2, and p201SFFV-miR30-LM02.4. Amplification of siRNA 
sequences human ENL3 and mouse LM02.1, mouse LM02.3 were never successful as point 
mutations always occurred.
n p r Figure 3.14- Digest of p201SFFV
3 -1 with Xhol and EcoRI.
Lane 1: ladder marker
Lane 2: sample
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Figure 3.15- Digest of miniprep DNA with Xhol and EcoRI to identify the clones containing 
desired vectors.
Lane 1-27: sample 1-27 
Lane 28: ladder marker
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3.5 . V ir u s  Tit r a t io n  f o r  A c h ie v in g  M a x im a l  In f e c t io n  E f f ic ie n c y  in  H a e m a t o p o ie t ic
CELLS
For the purpose of estimating functional virus titre in order to achieve high-level transduction 
in the haematopoietic cell lines as well as to get good reproducibility over the course of multiple 
viral preparations and experiments, it was then to define the MOI for different cell lines since 
MOI is cell-type dependent. MOI is the ratio of infectious virus particles to the number of cells 
being infected. The general theory behind MOI is to introduce one infectious virus particle to 
every host cell that is present in the culture. However, multiple copies of the viral integration 
may happen, which leaves a percentage of cells uninfected. This occurrence can be minimised by 
using a higher MOI to ensure that every cell is infected, such that the transduction can be 
optimised.
Titreing lentiviral vectors were performed by assessment of expression of eGFP transgene 
following 48 h post-transduction of E2A-HLF and LM02/BCL2 primary immortalised 
haematopoietic cell lines as well as BAF3, 32D, C ll (MLL-ENL) and SEMK2 haematopoietic 
cell lines with the a unrelated viral vector, which allowed us to estimate MOI for different cell 
types. Meanwhile, BAF3 cells were also transduced with a variety of viral vectors, including 
the 9 shRNA constructs (obtained from chapter 3.4.), which allowed us to make sure that 
different viruses infect the same cell line with more or less the same efficiency. To obtain MOI, it 
was first to work out the actual amount of the virus particles that have infected 1 ml of lx l0 4 
cells per 96-well. Based on the assumption that each cell was infected by one virus, lx l0 4 cells 
that presented 100% transduction was multiplied by the percentage of eGPF-positive cells 
obtained from the FACS analysis. The derived answer was then divided by the amount of virus
supernatant (pi) (5-folds serial dilution) used to infect the cells and then multiplied by 1000 to 
estimate the amount of the viral particles per ml. The virus titre of 1 MOI value for most of the
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7viruses that transduced BAF3 cells were approximately 3 x 1 0  cells per ml, as shown in Table
3.1 and Figure 3.16 (the representative sample, BAF3 infected with MLL shRNA construct) 
whereas LM 02 construct-containing viruses showed an 1 MOI of 10-folds less (Table 3.2 and 
Figure 3.17), suggesting that LM02 lentiviral construct is relatively inefficient to infect the 
cells.
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% Infected ce lls viral su p e rn a tan t (ul) viral particles/m l
85.20% 50 1.70 x 105
87.50% 10 8.75 x10s
72.70% 2 3.64 x 106
56.70% 0.4 1.42 x 107
25.10% 0.08 3.14 x 1 0 7^
5.63 x 107^9.00% 0.016
2.40% 0.0032 7.50 x 107
Table 3.1 Infection of BAF3 cells with 
p201 SFFV-miR30-MLL. 5-folds serial 
dilution of the viral supernatant is 
correlated with the decreased level of 
transduction efficiency. Virus titres 
(viral particles per ml) were calculated.
MOI=l
Figure 3.16. Plot of % infected cells against MOI shows S-shaped trend line. Since MOI=l was 
estimated to lie within the range (green line) where the gradient is constant, the midpoint (red 
circle) alone the green straight line was taken as the point for MOI=l (3.14 x 107 virus 
particles/ml).
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% Infected cells viral su p e rn a tan t viral particles/m l
69.00% 50 1.38 x 105
69.70% 10 6.97 x 105
37.50% 2 1.88 x 106
19% 0.4 4.75 x 106 *
9.00% 0.08 1.13 x 107 \
2.50% 0.016 1.56 x 107
0.90% 0.0032 2.81 x107
Table 3.2 Infection of BAF3 cells with 
p201 SFFV-miR30-LMO2.4. 5-folds 
serial dilution of the viral supernatant is 
correlated with the decreased level of 
transduction efficiency. Virus titres 
^ (v iral particles per ml) were calculated.
MOI=l
Figure 3.17. Plot of % infected cells against MOI shows S-shaped trend line. Since MOI=l was 
estimated to lie within the range (green line) where the gradient is constant, the midpoint (red 
circle) alone the green straight line was taken as the point for MOI=l (4.75 x 106 virus 
particles/ml).
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To compare the infectability of different cell lines, percentage of eGFP-positive cells were 
plotted against amount of virus supernatant (in Log scale) used to transduce the cells, as 
illustrated in Table 3.3 and Figure 3.18. The p201SFFV-miR30-MLL vector (representative 
sample) produced significant levels of transduction at an MOI of 10 in most of the cell lines 
except for LM02/BCL2 primary immortalised cell lines. SEMK2 and Cl 1 cell lines consistently 
produced higher transduction levels (approximately 98%) compared to BAF3 (85.2%). 
Apparently, SEMK2 cell line is the most infectable as high level of transduction can be reached 
with a low MOI of 0.5 (meaning that you inoculate 5 virus particle for every 10 cells) whereas 
LM02/BCL2 primary immortalised cell line is the least as higher MOI (> 100) is required to 
achieve effective transduction. Interestingly, loss of infection efficiency was observed at an MOI 
greater than 10 in BAF3 cell line, suggesting that there is certain range of MOI for optimal 
transduction in this cell line as BAF3 cell line might be sensitive to the purity of the virus 
supernatant. The result thus demonstrates that infectability, in terms of MOI, is in a cell-type 
dependent manner.
68
Table 3.3. Decreased percentage of infected cells is correlated with the 5-fold serial dilution of 
the virus supernatant. Virus titres (amount of virus particles per ml) were calculated.
A m ount of v irus (ul) A m ount of v irus partic les (ml) BAF3 32D C11 SEMK2 LM02/BCL2
50 1.57 x 106 85.20% 97.20% 93.50% 98.70% 61.00%
10 3.14 x 105 87.50% 94.70% 78.20% 99.10% 51.10%
2 6.28 x 104 72.70% 83.40% 54.90% 98.60% 21.20%
0.4 1.26 x 104 56.70% 72% 38.20% 96.60% 12.30%
0.08 2.51 x 103 25.10% 49.50% 19.30% 72.40% 4.80%
0.016 5.02 x 102 9.00% 28.60% 5.90% 30.50% 4.60%
0.0032 1.00 x 102 2.40% 25.30% 2.90% 16.70% 1.50%
Figure 3.18. Plot of % infected cells against MOI and amount of virus shows the infectability 
is cell-type dependent. SEMK2 cell line is the most infectable while LM02/BCL2 cell line is the 
least. Most cell lines, except for LM02/BCL2, show significant level of transduction at MOI=10 
to 100 that is 105 to 106 of the virus particles. Higher level of transduction in LM02/BCL2 cell 
line is expected to be achieved at an MOI > 100 (>106 of the virus particles)
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Since the assumption of infecting lx l0 4 cells in each 96-well by lxlO4 viral particles with 
100% transduction can not be true in practical, higher titre i.e. more than lxlO4 viral particles 
must be used to transduce the cells for effective infection. The estimation of virus titre (3.14 xlO7
virus particles per ml) for MOI=l (Table 3.1, Figure 3.16) allowed us to figure out the amount
of virus particles that is required to yield, for example, an MOI of 10 in BAF3 cell line for 
high-level transduction. As illustrated in table 3.3, calculation of amount of virus particles for the
most concentrated virus supernatant (50pl) was derived from 3.14 xlO4 virus particles per pi
times 50pl that gave 1.57 xlO6 virus particles in total. Due to 5-fold dilution, the number of 1.57
xlO6 virus particles was thus divided by 5 each time, and obtained the amount of virus particles 
of 1 xlO2 for the least concentrated virus supernatant. Table 3.3 and Figure 3.18 show an 
estimation of the amount of virus particles to achieve high-level transduction in different cell 
lines. For instance, to achieve almost 100% transduction in SEMK2 cell line, lx l0 4to lxlO5 
virus particles should be used. In contrast, much higher virus titre (more than lxlO7 virus 
particles) must be used to achieve high-level transduction in LM02/BCL2 cell line. Therefore, 
titreing gives the viral concentration of the supernatant, which allows one to know how many 
infectious particles are added in a given experiment that is important to define functional titre for 
efficient transduction as well as to provide reproducible data.
3.6 . E s t a b l is h m e n t  o f  K n o c k d o w n  E f f ic ie n c y
Having designed shRNAs that were predicted to load RISC efficiently with siRNAs specific 
for those sequences and constructed a set of miR30-based shRNA lentiviral vectors targeted to 
gene of interest, it was then important to determine whether effective knock-down of the target 
mRNA and its encoded gene product could be obtained. Following the transduction of the 
cells with lentiviral expression vector encoding a shRNA specific for the gene of interest, 
eGFP-positive cells were sorted and isolated for having high purity of the infected cells. 1 - to 2-
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week’s duration was given to allow the infected cells to proliferate so that substantial reduction 
in the level of expression of stable proteins encoded by the targeted mRNA can be observed.
3.6.1 MLL-ENL protein detection
It has been difficult to obtain a good knock-down in transduced cells by western blotting. 
All the proteins of interest to be detected by western blotting were myc-tagged. As illustrated in 
Figure 3.19, introduction of the p201SFFV-miR30-MLL and p201SFFV-miR30-ENLl into 
MLL-ENL immortalised haematopoietic cell line (C11) resulted in a marked and specific 
reduction in the level of exogenous MLL-ENL fusion protein compared to the control cells that 
were transduced with an irrelevant p201SFF-miR30-HLF. In theory, unrelated virus does not 
exert specific effect on the target, thus serve as a negative control. In contrast, no reduction was 
seen in the cells transduced with 201SFFV-miR30-ENL2 Authenticity of knockdown 
efficiency was confirmed by detection of unchanged expression levels of HSP90 loading 
control protein among the samples.
MLL-ENL (220 kDa)
Figure 3.19. MLL-ENL immortalised haematopoietic cell line (C11) was transduced with the 
indicated lentiviruses (MOI =10, cells transduced with nonspecific p201SFFV-miR30-HLF virus 
serve as control). GFP-expressing cells were sorted 7 days after infection. Whole-cell extract 
were analysed by western blotting for the indicated proteins.
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3.6.2 LM 02 protein and mRNA detection
Detection of LM02 protein in LM02/BCL2 immortalised primary haematopoietic cell line 
has been difficult. Having repeated this experiment several times, it has been assured that 
compatibility, affinity and activity of the primary and secondary antibody, transfer of the protein 
from the gel to the membrane as well as the amount of the SDS in the gel and buffer were not the 
possible causes. Loss of either BCL2 or LM02 expression in the immortalised cells would have 
caused cell death and therefore the possible explanations for the absence of the band indicating 
LM02 protein expression are the instability and low expression of LM02 protein in the cells. 
Finally, detection of LM02 protein was achieved by boiling the whole-protein extract in the 
RIPA buffer, gently mixed and span them immediately prior to loading. Figure 3.20 shows 
detection of both BCL2 (25 kDa) and LM02 (18 kDa). Cleary, the result showed no significant 
knock down in the cells transduced with p201SFFV-miR30-LM02.2 and 
p201SFFV-miR30-LM02.4 compared to the control uninfected cells and cells transduced with 
irrelevant virus.
BCL2 (25 kDa)
LM 02 (18 kDa)
Figure 3.20. LM02/BCL2 primary immortalised haematopoietic cell line was transduced with 
the indicated lentiviruses (MOI = 100, uninfected cells and cells transduced with nonspecific 
virus serve as controls). It shows relatively weak detection of LM02 protein expression in 
comparison to that of BCL2. Markedly, LM02 is expressed at exceedingly low level compared 
to BCL2 in the immortalised cells.
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RT-qPCR experiments were performed on RNA samples extracted from LM02/BCL2 
primary immortalised haematopoietic cells transduced with p201SFFV-miR30-LM02.2, 
p201SFFV-miR30-LM02.4 and the uninfected cells to assess the amount of knockdown of 
LM02 on an mRNA level. Expression levels of LM02 transcripts were quantified relative to the 
expression level of the endogenous housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). In addition to the transduction with specific LM02 shRNA 
constructs, the cells were also transduced with the irrelevant viral vector, p201SFFV-miR30-HLF. 
Figure 3.21 shows an up-regulation of relative mRNA expression level in all the transduced cells 
compared to the uninfected cells. To establish substantial knockdown at mRNA level, cells 
treated in the same condition were preferred for the comparison, thus, cells transduced with the 
irrelevant viral vector, rather than the uninfected cells, were used as the control for the analysis 
of the knockdown efficiency. Result from RT-qPCR indicated that RNAi did not succeed to 
induce significant degradation (<20% knockdown) of LM02 mRNA in the cells transduced with 
p201SFFV-miR30-LM02.2 and p201SFFV-miR30-LM02.4, which is concordant with the result 
obtained from western blotting analysis (Figure 3.20).
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Figure 3.21 RT-qPCR Analysis for the LM02 mRNA Degradation. LM02 mRNA up-regulation 
was observed in the cells transduced with both specific and irrelevant shRNA lentiviral vectors in 
comparison to the uninfected cells. Having p201SFFV-miR30-HLF transduced cells as a control 
(i.e. relative mRNA expression level = 1), mRNA expression levels in the cells transduced with 
p201SFFV-miR30-LM02.2 and p201SFFV-miR30-LM02.4 are at 0.84 and 0.93, respectively, in 
relation to the control (relative expression level = 1).
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3.6.3. E2A-HLFprotein detection
Different viruses that bearing different designs of HLF shRNAs for targeting E2A-HFL 
transcript were used to transduce the E2A-HLF primary immortalised cell line. To confirm the 
knockdown efficiency of p201SFFV-miR30-HLFl, p201SFFV-miR30-HLF2, p201SFFV- 
miR30-HLF3, and p201SFFV-miR30-HLF4, western blotting analysis was performed. 
Uninfected cells served as a negative control. Among the four different viruses, p201SFFV- 
miR30-HLFl and p201SFFV-miR30-HLF4 seemed to down-regulate E2A-HLF gene effectively, 
in comparison to the negative control (Figure 3.22). E2A-HLF knockdown seems to be true as 
the expression levels of loading control (p-Actin) are the same.
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Figure 3.22 E2A-HLF primary immortalised haematopoietic 
cell line was transduced with the indicated lentiviruses (MOI 
= 10, uninfected cells serve as control). It shows efficient 
knockdown of E2A-HLF gene by p201SFFV- miR30-HLFl 
and p201SFFV-miR30-HLF4.
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CHAPTER 4  
DISCUSSION
4.1 . E f f ic ie n t  In f e c t io n  o f  Q u ie s c e n t  C e l l s  b y  H IV -B a s e d  L e n t iv ir a l  Ve c t o r
Since the discovery that an RNAi pathway was conserved in mammals, the exploitation of 
this silencing response as a reverse genetic tool has evolved in concert with better understanding 
of its biochemical mechanism. In mammalian RNAi experiments, the long-term expression in 
the transduced cells is cell-type and promoter dependent. Lentiviral vectors based on HIV-1 
achieve entry through the nucleopores by utilising active transport mechanisms that delivering 
intron- containing sequences through the binding of the viral Rev protein to a cis-acting RRE 
whereas commonly used vectors based on murine oncoretroviruses rely on the passive 
mechanism of nuclear envelope breakdown during the cell cycle cell division prior to integration 
in host cell genome. Hence, in this study, HIV-1-based lentiviral vectors were preferred to 
oncoretroviral for infection especially because they stably integrate in nondidving quiescent cells 
such as HSCs, avoiding the use of prolonged cytokine to trigger cell cycling of HSCs that may 
induce differentiation together with proliferation, thereby leading to the loss of fundamental 
properties of HSCs during the transduction process.
4.2. L o w -L e v e l A c t iv ity  o f  CMVP ro m o te r  in H aem ato p o ie tic  C e l l  L ines
This study revealed that while efficient gene transfer to HSCs was achieved, the in vitro 
levels of transgene expression from internal CMV immediate early region enhancer- promoter 
were low, indicating 2nd generation of lentiviral vector was not yet optimised for long-term 
expression of gene of interest in mouse HSCs. Our finding is supported by a recent study 
showed that whereas the CMV promoter gave high levels of GFP gene expression in two 
nonhaematopoietic cell lines (293T and HT1080 cells), MFI has decreased by 10-12 fold in 
haematopoietic cell line (KGla cells). Similar findings have also been reported that lentiviral 
vectors using a CMV immediate early region enhancer-promoter to transcribe the gene of 
interest does not perform well in human HSCs (An et al. 2000;Ramezani, Hawley, & Hawley 
2000;Scharfmann, Axelrod, & Verma 1991). Such problem might be owing to the CMV
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promoter is often subject to extinction of expression and silencing in vivo, resulted from the 
natural defense strategies of the eukaryotic cells, such as presence of large stretches of compact 
heterochromatin serving as transcriptional barriers against integrated retroviruses in the cells and 
methylation of viral transcriptional element (An, Wersto, Agricola, Metzger, Lu, Amado, Chen, 
& Donahue 2000;Scharfmann, Axelrod, & Verma 1991). Thus, despite of the utility of HIV-1 
based lentiviral vectors for gene transfer into human HSPC subset have been established, 
nonetheless, the lentiviral vectors using internal CMV promoter presently in general use are not 
optimised for gene expression in HSPCs.
4.3. H ig h -L e v e l A c t iv ity  o f  SFFVP ro m o te r  in H aem ato p o ie tic  C e l l  L ines
High level activity of the SFFV enhancer has been shown to sustain throughout all stages 
and lineages of haematopoietic development, particularly in the context of oncoretroviral vectors 
(Baum et al. 1997). To augment transgene expression in HSCs, and to facilitate the analysis of 
transduced cells, the SIN HIV-1-based vector p201 containing WPRE, cPPT, RRE and eGFP 
genes under the transcriptional regulation of the internal CMV promoter was modified by 
replacing CMV promoter with the U5 part of the SFFV strain P long terminal repeat sequence. 
The result showed a significant increase of eGFP expression driven by SFFV in transduced 
haematopoietic cells, including primary immortalised cells and primary HSCs, with optimal 
transduction efficiency. Furthermore, effective activity of SFFV in the transduced cells has been 
observed 7 days post-transduction, interestingly, MFI (mean fluorescence index) has increased 
from 3 days post-infection to 7 days. The data has confirmed that the choice of the promoter 
manifests significant influence on the long-term expression of genes introduced in primary 
haematopoietic cells by new generation lentiviral vectors. Establishment of high-level and 
stable long-term expression of the lentiviral vector containing SFFV promoter in HSCs is in 
consistent with a recent study. They found that the incorporation of the U3-LTR of SFFV used 
as an internal promoter, together with WPRE, cPPT and termination sequences in the vector
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backbone, provided between a 20- and 73-fold increase in transgene expression in engrafted cell 
lineages compared to a basic vector containing the CMV promoter (Demaison, Parsley, Brouns, 
Scherr, Battmer, Kinnon, Grez, & Thrasher 2002).
4.4 . Vir u s  Tit r a t io n
Virus titration was performed in order to determine the optimal concentration of the 
lentiviral particles used for achieving high-level transduction in the (primary) haematopoietic 
cells. In principle, poor infection can be improved by increasing virus titreing. HIV-1-based 
lentiviral vector containing an internal SFFV promoter has exhibited high-level transduction in 
haematopoietic cells, unfortunately, the infection rate of all the cells that have transduced at 
estimated MOI has declined from 100% to as low as 20% after the candidate shRNAs were 
cloned into the viral vector. It was first thought that inefficient transduction might due to bad 
DNA quality, unhealthy cells for transduction, stale cytokines for cells growth, or inappropriate 
timeframe for the transduction process. However, favourable percentage of eGFP-positive cells 
was not yielded from the technical improvement. Furthermore, the limitations of virus titreing 
are two-fold: it assumes that the level of expression of all integrated vectors is above the 
detection threshold of the assay and it may not distinguish cells with multiple copies of vector. 
Of note, it is important to consider transduction rate. A respectable 30% transfection efficiency 
could give no more than a 30% drop in target mRNA or protein expression levels even if the 
shRNA was 100% effective. The transduction efficiency problem was overcome by cell sorting 
that yielded high purity of eGFP-positive cells so that interpretable mRNA and protein 
knockdown data can be obtained. Furthermore, higher titreing is likely to induce apoptosis in 
some cell lines. The toxicity possibly arises from the VSV-G envelope protein, from the 
high-level transgene expression, from copurified contaminants in the vector preparation, or from 
a combination of these factors (Demaison, Parsley, Brouns, Scherr, Battmer, Kinnon, Grez, & 
Thrasher 2002).
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4.5. E s ta b lis h m e n t o f  K n o ckd o w n  E ff ic ie n c y
Once the silencing capability of several candidates of shRNA for every target gene has been 
evaluated by western blotting or/and RT-qPCR at the level of exogenous protein or/and mRNA, 
respectively. Western blotting analysis showed that p201SFFV-miR30-MLL and 
p201SFFV-miR30-ENLl, but not p201SFFV-miR30-ENL2, effectively knocked down 
MLL-ENL expression; p201SFFV-miR30- HLF1 and p201SFFV-miR30-HLF4, but not 
p201SFFV-miR30- HLF2 and p201SFFV-miR30-HLF3, significantly down-regulated E2A-HLF 
expression. It suggested that even if shRNA is optimally designed by the computer algorithms 
and efficiently incorporated into RISC, there is still no guarantee that it will be effective. Current 
evidence suggest that fully functional shRNA can be entirely ineffective due to the fact that RISC 
complexes are not able to access mRNA target sites that are sequestered by another 
macromolecular interaction or by even relatively weak RNA secondary structure (Dallas & 
Vlassov 2006). Instability and low expression of LM02 proteins in the BCL2/LM02 
immortalised cell line were demonstrated by western blotting analysis, which made the LM02 
protein detection difficult. Both RT-qPCR and western blotting analysis showed ineffective 
LM02 knockdown by p201SFFV-miR30-LM02.2 and p201SFFV-miR30-LM02.4, thus, new 
LM02 shRNA oligos need to be designed.
4.6. D o w n s tre a m  T a rg e ts  o f E2A-HLF
Several downstream targets of E2A-HLF have been previously identified by other groups 
using cDNA representational difference analysis and include Annexin VIII, SRPUL, Slug, 
Groucho-related genes and Runx\/AML-1 and Annexin II(Dang et al. 2001;Inukai et al. 
1999;Kurosawa et a l 1999;Matsunaga et al. 2004). Annexin VIII, SPRUL and Slug were 
identified as E2A-HLF targets in the E2A-HLF-expressing UOC-B1 leukaemic cell line induced 
to express a dominant negative form of E2A-HLF that lacks transactivational activity. Of the 
previously identified targets of E2A-HLF, only over-expression of Slug, a mammalian
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homologue of CES-1, confers some resistance to IL-3 withdrawal-induced apoptosis in Baf-3 
cells, suggesting its antiapoptotic activities in pro-B cells (Kurosawa, Goi, Inukai, Inaba, Chang, 
Shinjyo, Rakestraw, Naeve, & Look 1999). However it is not expressed in all leukaemia cell 
lines that express E2A-HLF (Inukai et al. 1999). Further study using microarray experiment by 
Jenny Yeung assessed expression of these E2A-HLF target genes. However, Slug was not 
expressed or over-expressed by the inducible E2A-HLF clones, also Annexin //an d  Runxl, were 
expressed, but were not changed by the expression of E2AHLF, suggesting these genes are not 
essential for the leukaemogenic activities of E2A-HLF. Thus, it remains to unravel whether 
LM02 contributes to the development of leukaemia by further studies.
4. 7. F u t u r e  W o r k s
The most efficient lentiviral vectors against specific genes will be used to infect leukaemic 
cells and the effect on aspects of the leukaemic phenotypes such as the cell cycle, apoptosis and 
immortalisation will be tested, which in turn, to determine the importance of E2A-HLF and its 
target gene, LM02 as well as MLL-ENL during leukaemogenesis, also the functional role played 
by MLL-ENL during normal haematopoiesis. Phenotypic changes upon introduction of 
shRNAs into the target leukaemic cells could be assessed by using antibodies to identify cell 
surface markers (e.g. B220, cKit, CD 19, Mac-1 and Gr-1), by colony-forming assay to trace cell 
fate or by Annexin V assay to detect apoptosis at a very early stage. Inducible and conditional 
RNAi systems can be used to study gene function in vivo in animal model. GFP-miR30-shRNA 
vector can be used in Tet-on system to study biological consequences of inactivation of 
leukaemogenic gene in vivo. Primary immortalised HPCs transduced with Tet-on lentivector 
carrying specific silencing cassette can be transplanted into mice, which in turn, can initiate the 
development of leukemia. In order to know if the knockdown of abnormally expressed genes 
renders the leukaemic cells to undergo cellular differentiation or apoptosis, doxycycline can be 
introduced into the mice by oral administration or direct injection. Presence of doxycycline
81
relieves transcriptional repression, thus, allowing transcription of shRNA from promoter to 
induce silencing effect. The identification and characterisation of dysregulated genes in rare 
LSCs using lentiviral-based RNAi together with a series of approaches will benefit the design of 
the antileukaemic treatments to specially target these LSCs, and to effectively cure and prevent 
childhood ALL relapse.
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CHAPTER 5 
CONCLUSION
Childhood leukaemias have traditionally been treated on the basis of phenotypic 
characteristics, such as morphology, cell-surface markers and cytogenetic aberrations by 
reducing the bulk population. Nevertheless, lack of durable response occurs in most cases, 
suggesting that the existing treatment used may not effectively target the LSC population within 
a leukemia. Indeed, the failure of the current therapeutic regimens is likely related to the 
resistance and persistence of LSCs.
The microarray technology has enabled comparison of expression profiles in malignant 
cells and their normal cellular counterparts, thus allowed for identification of new diagnostic or 
therapeutic targets. A set of genes have been found to be dysregulated by E2A-HLF and 
MLL-ENL fusion in pro-B cells. To obtain better understanding of the biological and 
molecular features of the cells that initiate and sustain ALL, a number of experiments, including 
RNAi-mediated gene knockdown, are required to fully elucidate the role of E2A-HLF, 
MLL-ENL and their target genes in leukaemogenesis and inhibition of apoptosis, which is an 
essential step in the development of novel agents effective against the childhood ALL.
Since inhibition of the abnormally up-regulated target gene, LM02, of E2A-HLF by 
chemotherapeutic agents may improve treatment and clinical outcome, lentivirus-based RNAi 
was used to perform gene silencing in the immortalised HPCs. E2A-HLF and MLL-ENL gene 
knockdown were also performed to determine their importance in HPCs. In this study, 
HIV-based lentiviral vector for high-level transduction of the primary HSPCs have been 
optimised by replacing internal CMV promoter with the U5-LTR of SFFV. The miR30-based 
shRNAs could very efficiently be expressed from the promoter such that single-copy proviral 
integrants provide high-level knockdown. The shRNA oligos against human MLL, ENL, HLF 
and mouse LM02 were subcloned into this p201SFFV miR30-based lentiviral vector. 
Furthermore, GFP fusion downstream from the SFFV promoter not only was used to sort for
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reporter-positive cells but also to normalise and monitor transduction levels to accurately assess 
knockdown efficiencies. pSFFV-miR30-MLL and pSFFV-miR30-ENLl showed efficient 
and sequence-specific gene silencing by endogenously expressed shRNAs in mammalian 
haematopoietic cells while pSFFV-miR30-ENL2 failed to reduce MLL-ENL gene expression. , 
pSFF V-miR3 0-HLF1 and pSFFV-miR30-HLF4 but not pSFFV-miR30-HLF2 and 
pSFFV-miR30-HLF3 have knocked down E2A-HLF gene expression. Unfortunately, high-level 
knockdown was not observed in the LM02/BCL2 primary immortalised cells transduced with 
pSFFV-miR30-LMO2.2 or pSFFV-miR30-LMO2.4. It has been generally accepted that 
knock-down of a target gene by > 80% will only be achieved with about one-third of the 
shRNAs tested despite of a series of design criteria and technologies that should allow effective 
shRNA expression vectors specific for mRNA have been followed. It remains to be seen if novel 
principles and insight will lead to future shRNA design criteria that give efficient target gene 
knock-down with every shRNA analysed. Gene delivery by infecting haematopoietic cells with 
a lentiviral vector bearing a miR30-based shRNA sequence expressed from SFFV promoter 
seems to be a very useful tool to perform RNAi experiment in the mammalian haematopoietic 
cells.
Over the past decades, the mainstay of leukemia therapy has been to induce complete 
remission and to consolidate this with further courses of chemotherapy. Validation of the 
downstream targets of E2A-HLF and MLL-ENL and elucidation of the pathogenic pathways in 
childhood leukaemias may hold great promise for further improving cure rates by developing 
drugs against specific target molecules required for the initiation and progression of leukaemia.
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